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Chapter 1 
 
Introduction 
 
 
Overview 
 The central focus of this thesis is the pathogenesis of cardiomyopathy 
caused by loss of dystrophin, and how this may be a unifying mechanism for 
cardiac dysfunction in inherited and non-inherited heart disease.  Dystrophin is 
most notable for being identified as the cause of Duchenne muscular dystrophy 
(DMD), a lethal disease of muscle wasting first described in the mid-1800's 
[1,2,3,4].  Historically, the majority of basic and clinical research on DMD has 
been focused on skeletal muscle.  However, DMD also causes a significant 
cardiomyopathy which causes ~20% of deaths in DMD [5,6].  More recently, 
dystrophin has also been implicated in non-dystrophic heart failure due to a 
variety of causes (Table 1-1).  The purpose of this chapter is to introduce and 
describe dystrophin, the inherited and non-inherited diseases it is associated with, 
and to point out gaps in our knowledge of dystrophin's physiological function 
which are addressed in the later chapters of this thesis.   
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Clinical description of Duchenne muscular dystrophy 
 DMD is the most common inherited muscular dystrophy, occurring in 
approximately 1 in 3500 males [7].  DMD affects patients very early in life, 
presenting as general weakness within the first few years, particularly within the 
lower limbs and postural muscles.  Young patients with DMD will typically display 
a characteristic method of righting themselves from a supine position by using 
their limb muscles to bring the torso to an upright position.  This behavior, called 
Gowers' sign, was first described by William Richard Gowers in 1865 [8].  In the 
modern clinical setting, a diagnosis of DMD is also accompanied by muscle 
biopsy and/or genetic testing to confirm lack of dystrophin protein and the 
presence of a mutation in dystrophin, respectively [9].  Affected muscles of DMD 
patients also show enlargement of certain muscle groups, particularly in the 
calves, despite muscle weakness [2,3,4].  Microscopic analysis of muscles from 
DMD patients reveals that this enlargement is not hypertrophy, but is due to 
massive replacement of muscle with fat and fibrotic tissue, a pseudohypertrophy 
[3].  The presence in the serum of cytoplasmic muscle enzymes such as muscle 
creatine kinase, a marker of muscle damage, is also a hallmark of DMD 
[10,11,12].  In the years following initial diagnosis, DMD patients experience 
progressive declines in strength and mobility accompanied by joint contractures 
[13,14,15].  Patients typically lose the ability to ambulate at approximately 10 
years of age [16].  Death typically occurs in the second decade of life, the most 
common cause of which is respiratory failure brought on by severe wasting of the 
diaphragm [6,17,18].  
3 
 
 In addition to skeletal muscle disease, DMD patients also have a 
pronounced dystrophic cardiomyopathy, which has been noted in DMD patients 
since the very first descriptions of the disease by Conte and Gioia [1].  Much like 
skeletal muscle, cardiac involvement is progressive in DMD, but generally 
proceeds at a slower rate when compared with skeletal muscle [19].  Subclinical 
cardiomyopathy is nearly universal in DMD patients over 6 years of age [19].  
Specifically, diastolic dysfunction, tachycardia and ECG abnormalities, most 
commonly prominent R waves in the precordial leads, are common in the early 
(ambulatory) stage of the disease [20,21,22,23].  Subsequent study of autopsy 
specimens from DMD patients has linked these ECG defects with dystrophic 
replacement of the posterobasal portion of the left ventricle with fibrotic tissue, 
similar to the processes occurring in skeletal muscle [21].  As disease progresses, 
DMD patients develop clinical cardiomyopathy, which is in most cases a dilated 
cardiomyopathy [5,19].  The incidence of dilated cardiomyopathy increases 
dramatically after age 10, having a prevalence of approximately 25% between 
ages 10-14, 50% between ages 14 and 18, and over 70% in patients over 18 
years of age [19].  This cardiomyopathy often develops into frank heart failure 
and accounts for 20% of deaths in DMD patients [5,6].  Interestingly, there is a 
disconnect between the number of patients with diagnostically determined DCM 
and those with symptomatic cardiac involvement.  Less than 50% of DMD 
patients with DCM report having any symptoms of cardiac involvement [19].  This 
surprising observation is likely due to the reduced sensitivity of wheelchair-bound 
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DMD patients to exercise intolerance brought on by severe skeletal muscle 
wasting which masks the significance of cardiomyopathy in DMD.   
 
Identification of the DMD gene 
 Despite the careful and discriminating characterization of the clinical 
presentation of DMD dating back through the mid-19th century [1,2,3,24], the 
genetic foundation of this debilitating disease remained unknown through most of 
the 20th century.  The clinical manifestations of DMD did, however, provide some 
clues about its genetic underpinnings.  The documentation of families with DMD 
clearly established it as a heritable disease [2,3].  Additionally, DMD affected 
males almost exclusively and was inherited maternally, suggesting an X-linked 
recessive mode of inheritance [1,2,3].  Also, the frequency of DMD is relatively 
high [7,24], suggesting that the DMD gene may be very large or perhaps prone to 
mutation.  Armed with this knowledge and aided by advances in molecular 
genetics, the genetic cause of DMD began to emerge in the 1980’s.  Interestingly, 
some of the most important studies leading to the identification of the DMD gene 
focused on females.  These cases are exceptionally rare, but in each case 
patients were found to have chromosomal translocations between the X 
chromosome and various other autosomes [25,26,27,28].  Specifically, these 
translocations all occurred on the short arm of the X chromosome at Xp21 
[25,26,27,28].  A series of genetic linkage studies utilizing known DMD mutations 
identified a particular locus, DXS164, on the X chromosome [29,30,31,32,33].  A 
group led by Dr. Louis Kunkel then used probes generated from this locus to 
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screen a fetal muscle cDNA library and identified a large (14 kb) cDNA [34].  
Sequence fragments of this cDNA were found to detect deletions in the DMD 
gene at a high rate in DMD patients, supporting its identity as the cDNA of the 
DMD gene [34].  Antibodies created by immunization of animals with peptides 
derived from this cDNA detected a ~400 kDa protein in muscle, which was not 
detected in DMD patients [35].  This provided strong evidence that the gene 
residing at the DXS164 locus was the DMD gene.  Further characterization of the 
DMD gene showed it to be massive, spanning over 2 million base pairs, 
containing over 75 distinct exons and multiple independent promoters 
[36,37,38,39,40].  To this day, the DMD gene is the largest known gene in the 
human genome.  There are numerous isoforms and splice variants of the DMD 
gene expressed in various tissues throughout the body (Figure 1-1) [38,41,42,43].  
The dominant isoform expressed in striated muscle is a 427 kDa protein which 
was given the name dystrophin [35]. 
 It should also be mentioned that mutations in the DMD gene also cause 
Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy, allelic 
variants of DMD [44].  BMD is a mild form of muscular dystrophy compared with 
DMD, with patients maintaining ambulation through 15 years of age [13].  There 
is significant variation in the onset in severity of symptoms, with some BMD 
patients maintaining ambulation through the sixth decade [45].  The discrepancy 
in severity between DMD and BMD can, in general, be explained by the “reading 
frame rule”.  In short, mutations which disrupt the reading frame and cause 
protein truncation will result in DMD [46,47].  Mutations which do not disrupt 
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dystrophin’s reading frame, including deletions and insertions, which can be quite 
large, tend to cause BMD [45,46,47].  These are general rules, to which there are 
numerous exceptions including DMD-causing missense mutations and in-frame 
deletions that cause DMD.  A more detailed discussion is included in this chapter 
under the heading, “Physiological role of dystrophin in striated muscle”.   
X-linked dilated cardiomyopathy is also caused by mutations in the 
dystrophin gene [48], but in this case significant cardiomyopathy is present with 
little to no wasting of skeletal muscle [49].  The onset of clinical cardiac 
involvement occurs at approximately 15-20 years of age and is followed by a 
precipitous decline in cardiac function and often death within one year of 
diagnosis [48,49].  Although the genetic mutations which cause X-linked dilated 
cardiomyopathy have been determined in numerous families, the mechanisms by 
which these mutations cause heart disease vary.  Previous reports have 
documented X-linked dilated cardiomyopathy families in which dystrophin content 
from the heart is drastically reduced due to mutations which cause aberrant exon 
skipping [50,51], missense mutations [52], insertions within the 5' untranslated 
region of the DMD gene [53,54,55], and in-frame deletions [51,56,57].  In some 
cases dystrophin content is reduced specifically in the heart but in other cases 
normal levels of protein are detected in both skeletal and cardiac muscle.  It is 
unclear why some mutations specifically affect expression of dystrophin in the 
heart.  However, in some cases, it has been shown that mutations which prevent 
expression of the muscle isoform of dystrophin are compensated for by 
expression of the similar cortical and Purkinjie isoforms of dystrophin (Dp427c 
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and Dp427p, respectively) in skeletal muscle but not in cardiac muscle (Figure 1-
1) [53,54,55].  The reasons for this lack of compensation in cardiac muscle is not 
fully understood but may involve dystrophin muscle enhancer-1, which resides 
downstream from dystrophin’s muscle promoter [58].  This genetic element has 
been shown to enhance expression of the cortical and Purkinjie promoters in 
skeletal muscle, but not in the heart [59]. 
 
Biochemical and molecular characterization of dystrophin 
 Analysis of the primary amino acid sequence of dystrophin was first 
carried out by Dr. Louis Kunkel, whose research team described a 3685 amino 
acids protein that was predominantly hydrophilic and rod-shaped [60].  The 
predicted rod shaped structure of dystrophin has been verified by electron 
microscopy [61,62].  Structurally, the dystrophin protein is divided into 4 major 
domains: an N-terminal actin binding domain, a large central rod domain, a 
cysteine-rich domain, and a C-terminal domain (Figure 1-2a).  The N-terminal 
250 amino acids of dystrophin contain two anti-parallel calponin homology 
domains that show significant homology with the actin-binding domain of α-
actinin [63,64].  Truncated recombinant proteins containing this N-terminal 
portion of dystrophin have been shown to bind actin, confirming dystrophin's actin 
binding activity [65,66,67,68].  The next ~3000 amino acids constitute the central 
rod domain of dystrophin, which contains 24 triple helical homologous repeats.  
These repeats have homology to α-actinin and spectrin, which contribute to 
dystrophin’s rod-like structure.  Additionally, before repeat 1 and after repeats 3, 
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19, and 24 are 4 hinge regions [69].  Numerous proline residues within these 
hinge regions disrupt the helical rod domain of dystrophin and promote flexibility 
within the protein [69].  Additionally, spectrin-like repeats 11-17 contain 
numerous basic residues which constitute a second actin binding domain and 
contributes significantly to the dystrophin’s actin binding activity [68,70].  The 
next section of ~400 amino acids is known as the cysteine-rich domain, due to its 
relative abundance of cysteine residues compared to the rest of dystrophin [60].  
This domain contains a WW motif, 2 EF hand motifs, and ZZ motif [60,71,72].  
Finally, the most C-terminal ~300 amino acids are important for dystrophin's 
interaction with other proteins and will be discussed in detail below. 
 
Dystrophin's place in muscle: subcellular localization and the dystrophin-
glycoprotein complex 
 The identification of the DMD gene and creation of antibodies against the 
dystrophin protein allowed for the characterization of dystrophin's subcellular 
localization and provided clues to its physiological function.  Dystrophin is 
localized to the periphery of striated muscle, specifically located on the 
cytoplasmic face of the sarcolemma [73,74,75,76,77,78,79].  Further studies 
reveal that when longitudinal sections of skeletal muscle fibers are visualized, 
dystrophin shows a striated pattern and colocalizes with the costameres, the 
subsarcolemmal protein assembly which links the sarcomeres with the 
sarcolemma [76,77,80].  In cardiac myocytes, dystrophin also appears to localize 
at the t-tubules [75].  This finding was particularly informative with regards to 
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dystrophin's acting binding function and suggested that dystrophin interacted with 
cytoplasmic actins (β or γ) rather than with sarcomeric α-cardiac or α-skeletal 
muscle actin.  Experiments in peeled muscle fibers suggest that dystrophin 
interacts with γ-cytoplasmic actin in skeletal muscle [81].  Complimentary studies 
have yet to be carried out in cardiac myocytes.    
 Dystrophin's interaction with the sarcolemma remained somewhat of an 
enigma, especially given dystrophin's nature as a hydrophilic rod shaped protein 
[60].  The first clues into the nature of dystrophin’s interaction with the 
sarcolemma were provided by a group led by Kevin Campbell, who showed that 
dystrophin could be detected in by wheat-germ agglutinin chromatography of 
digitonin-solubilized muscle extracts [82], suggesting that dystrophin was 
associated with a glycosylated integral membrane protein.  Subsequent analysis 
showed that dystrophin was part of a large, oligomeric complex containing 
numerous glycoproteins [83,84].  Due to dystrophin’s prominent role in its 
discovery and the numerous glycoproteins present, this complex was given the 
name dystrophin-glycoprotein complex, or DGC (Figure 1-2b) [83,84].   
 The DGC is composed of several membrane-spanning and membrane-
associated proteins including the dystroglycans, sarcoglycans, dystrobrevins, the 
syntrophins, and sarcospan.  The dystroglycans, α and β, are discreet proteins 
derived from a common gene via post-translational polypeptide cleavage 
[85,86,87].  β-dystroglycan is a transmembrane protein which binds to the C-
terminal end of dystrophin [88,89,90].  Specifically, dystrophin interacts with β-
dystroglycan via the WW, EF hand, and ZZ motifs in the cysteine-rich domain 
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[91,92,93].  α-dystroglycan is an extracellular protein that interacts with β-
dystroglycan [85,86,87].  The core α-dystroglycan protein is 75 kDa but is highly 
glycosylated with the mature protein appearing at ~156 kDa by gel 
electrophoresis [85].  α-dystroglycan binds the extracellular matrix protein 
laminin, and proper glycosylation of α-dystroglycan is crucial for its laminin 
binding function [85,94,95].  Proper glycosylation of α-dystroglycan is mediated 
enzymatically by glycosyltransferases, mutations in which alter normal 
glycosylation, disrupt laminin binding, and cause several forms of so called 
glycosylation-deficient muscular dystrophy [94,96].  Collectively, the interactions 
of dystrophin and the dystroglycans with actin and laminin, respectively, form a 
mechanical linkage between the cytoskeleton and the extracellular matrix (Figure 
1-2) [95].   
 In addition to dystrophin and the dystroglycans, the DGC also contains the 
sarcoglycan complex.  In striated muscle, the sarcoglycan complex is composed 
of α, β, γ, and δ sarcoglycan [97].  The sarcoglycans are transmembrane 
proteins expressed from discreet genes [98,99,100,101,102].  The sarcoglycans 
do not directly participate in the mechanical tether formed by dystrophin and the 
dystroglycans, but clearly play an important role in striated muscle as evidenced 
by the limb-girdle muscular dystrophies (types 2C, 2D, 2E, and 2F) caused by 
mutations in these genes [98,103,104,105,106,107]. 
 The transmembrane protein sarcospan is also a part of the DGC [108].  
Sarcospan appears to be dispensable for muscle function since it has not been 
associated with any known diseases and knockout mice show no signs of 
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dystrophy [109,110].   However, transgenic overexpression of sarcospan 
ameliorates muscular dystrophy in dystrophin-deficient mice associated with 
increased expression of DGC proteins, suggesting a role in stabilizing the DGC 
[111].  
 In addition to dystrophin, the DGC also contains other cytoplasmic 
proteins, the dystrobrevins and syntrophins.  The dystrobrevins share significant 
homology with coiled coil domains within dystrophin’s C-terminus [112,113].  
Dystrobrevins interact with dystrophin and its homolog utrophin through these 
homologous coiled coil domains [114].  In skeletal muscle, α-dystrobrevin-2 is the 
primary dystrobrevin isoform associated with the DGC, with α-dystrobrevin-1 
associating primarily with utrophin at the neuromuscular junction [115,116].  
Genetic ablation of α-dystrobrevin causes mild muscle wasting but, curiously, 
does not cause defects in muscle function [117,118].  In addition to dystrophin, 
dystrobrevin also interacts with the syntrophins.  Syntrophins are cytoskeletal 
proteins which interact with dystrobrevin via a pleckstrin homology domain 
[119,120,121,122].  In skeletal muscle, the α1- and β1- isoforms interact with the 
DGC at the sarcolemma, whereas in cardiac muscle the β2 isoform is also found 
at the sarcolemma [116,123].  In addition to dystrobrevin, syntrophins also bind 
to homologous sequences in the C-terminal domain of dystrophin [116,120,124] 
and thus each DGC complex is associated with 2 syntrophin proteins.  
Syntrophins also contain a PDZ domain within the most N-terminal PH domain 
which recruits other proteins to the DGC including, nNOS, aquaporin-4, 
diacylglycerol kinase-ζ, and ion channels [125,126,127,128,129,130,131].  
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Genetic ablation of α1-syntrophin does not cause muscle defects, suggesting 
that it is not essential for muscle function [130]. 
 Although not technically a part of the DGC, the dystrophin homolog 
utrophin plays an important role in the pathogenesis of DMD.  Utrophin shares 
significant homology with dystrophin and has a similar 4 domain structure [132].  
Utrophin binds cytoskeletal actin and β-dystroglycan as well, although with 
biochemically distinct modes of interaction [133,134,135].  Utrophin is highly 
expressed in developing muscle but largely restricted to the neuromuscular 
junction in adult muscle [136,137].  Expression of utrophin is enhanced in the 
absence of dystrophin in some models of DMD, being found at the sarcolemma 
in the niche typically occupied by dystrophin (see discussion on mdx mice below) 
[138,139,140].  These observations have led to the hypothesis that utrophin 
plays a role in DMD pathogenesis and may be a therapeutic candidate for gene 
delivery.  
 On the whole, the DGC is a multimeric, membrane spanning protein 
complex, the constituents of which can be biochemically co-purified and are 
expressed in stoichiometric ratios [83,84,141].  Biochemically, titration with the 
detergent n-octyl beta-D-glucoside further resolves the DGC into 3 
subcomplexes: Dystrophin/dystrobrevin/syntrophins, the dystroglycans, and the 
sarcoglycans [142].  Aside from being a purely biochemical distinction, the 
interaction of proteins within these subcomplexes affect the stability of the DGC.  
For instance, loss of a sarcoglycan from the DGC typically causes a drastic 
reduction in the membrane expression of the other sarcoglycans while having a 
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much less dramatic effect on the other components of the DGC 
[101,103,105,143,144].  Dystrophin plays a crucial role in the stability of the DGC 
in skeletal muscle, the lack of which causes a dramatic reduction in all DGC 
components [145].  This is not the case in cardiac muscle, however, where DGC 
expression is largely unaffected by loss of dystrophin [146].  The reason for this 
discrepancy between skeletal and cardiac muscle is not known. 
 
Physiological role of dystrophin in striated muscle 
 Mdx Mouse.  Before discussing the function of dystrophin in striated 
muscle, it is first necessary to introduce the primary animal model used to carry 
out these physiological studies, the X chromosome-linked muscular dystrophy 
(mdx) mouse.  The mdx mouse was identified in a screen for glycolytic enzyme 
mutants due to the presence in the serum of muscle pyruvate kinase [147,148].  
The mdx mouse harbors a spontaneous point mutation in exon 23 of the DMD 
gene which causes truncation of the dystrophin protein at spectrin-like repeat 7 
within the N-terminal portion of the rod domain [149].  This truncated protein is 
degraded by the proteasome, resulting in a functional loss of dystrophin in 
striated muscle [150].  The mdx mouse displays many of the hallmarks of DMD, 
including muscle wasting, cardiomyopathy, fibrotic replacement of muscle, and 
the presence of muscle specific enzymes in the serum [147,151,152].  One 
significant difference between mdx mice and DMD patients is the severity of 
muscle wasting.  DMD is characterized by severe muscle wasting and premature 
death, whereas the mdx mouse has only ~20% reduced lifespan and, with the 
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exception of the diaphragm, mild muscle wasting [17,147,152,153].  The reason 
for this discrepancy in disease severity between mdx mice and DMD patients is 
not fully understood, but may be due to compensatory expression of utrophin (to 
~5% molar equivalent of normal dystrophin expression) in mdx mice [134,154].  
Dystrophin/utrophin double knockout mice have a much more severe dystrophic 
phenotype than mdx mice and expression of full length or engineered micro-
utrophins can potently prevent dystrophy in mdx mice [155,156,157,158,159].  
Additionally, a recent study has identified a gene, cytidine monophosphate–sialic 
acid hydroxylase (CMAH), involved in modifying extracellular sugar moieties that 
is active in mice but not in humans due to genetic divergence [160].  Knockin 
mice expressing the human form of the CMAH gene on a mdx background have 
a more severe phenotype than normal mdx mice [160].  Alternatively, previous 
reports have shown that the dystrophic phenotype of mdx and other dystrophic 
mice can be significantly altered by crossing them onto discrete inbred mouse 
strains, suggesting that genetic background is an important determinant of 
disease severity in dystrophic mice [161,162,163].  To determine the influence of 
genetic background  on cardiac function in inbred mice, in Chapter 2 of this 
dissertation I quantitatively assessed cardiac function in several commonly used 
strains of inbred mice.  Despite the mild phenotype of mdx mice, the vast majority 
of studies on dystrophin's physiological function have been carried out in this 
model. 
 GRMD dog.  In addition to mdx mouse, the golden retriever muscular 
dystrophy (GRMD) dog has also served as a model for physiological studies on 
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DMD.  This model harbors a spontaneous mutation within the splice acceptor site 
of intron 6 of the DMD gene [164] which is expected to cause a premature stop 
codon within exon 8 and lead to the production of a drastically truncated protein.  
Interestingly, in this model a small amount of nearly complete dystrophin (~390 
kDa) is expressed due to splicing adaptations which are not currently understood 
[165].  GRMD dogs have a severe dystrophic phenotype in skeletal muscle as 
characterized by profound muscle wasting, fibrosis, and elevation of serum 
creatine kinase [166,167,168].  Additionally, GRMD dogs show a pronounced 
cardiomyopathy characterized by myocardial wasting and fibrosis [169], 
contractile dysfunction [170], and dilated cardiomyopathy [171].  Because the 
severity of muscle wasting in the skeletal and cardiac muscle of GRMD dog is so 
similar to DMD patients, this animal model is considered the “gold standard” for 
large animal DMD research.  
 Dystrophin as a mechanical stabilizer of the sarcolemma.  As described 
above, the DGC provides a mechanical linkage between the cytoskeletal and the 
extracellular matrix localized to the costamere (Figure 1-2) [95].  Previous studies 
suggest that the costamere is a conduit for the lateral transmission of force 
generated in the sarcomeres to the extracellular matrix [172,173].  These findings 
along with the findings that dystrophin contains flexible hinge regions have led to 
the hypothesis that dystrophin acts to transmit force generated by the 
sarcomeres and also as a molecular shock absorber, stabilizing the membrane 
during the rigors of contraction and relaxation.  This hypothesis is in line with the 
findings of increased levels of muscle cytoplasmic enzymes in the serum and the 
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findings that mdx skeletal muscle is highly susceptible to injury brought on by 
mechanical stresses including hypo-osmotic stress, lengthening contractions, 
and exercise [10,11,12,174,175,176,177].  Increased susceptibility to injury in 
mdx mice is associated with decreased force production, decreased lateral force 
transmission, and increased membrane permeability, but not with reductions in 
the force generating capacity of the sarcomeres, suggesting that the primary 
defect resides in the sarcolemma [174,177,178,179,180].   The role of dystrophin 
appears to be similar in cardiac muscle, where isolated mdx cardiac myocytes 
are more susceptible to membrane damage due to passive stretch or hypo-
osmotic stress [181,182].  This mechanical injury is associated with increased 
membrane permeability in the absence of change in sarcomeric force production 
[181,182] (Metzger, J.M., unpublished observations).  Interestingly, when the 
tensile strength of the sarcolemma is tested directly there is no significant deficit 
in mdx mice [183].  Mdx muscle does, however, show aberrant reductions in 
sarcolemma folding [184].  The apparent excess of sarcolemma due to folding is 
necessary to mitigate the forces of mechanical stretch in normal muscle, 
suggesting that the mechanical instability of the membrane in mdx mice is due to 
lack of available membrane surface area during stretch [185].   
 The theory that dystrophin acts primarily as a tether to mechanically 
stabilize the sarcolemma suggests that its actin- and dystroglycan-binding 
properties are the most critical for its function.  Given the structural complexity 
and numerous interacting partners of dystrophin, a precise determination of the 
structural domains necessary for dystrophin’s physiological function can be 
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challenging.  Analysis of the mutations in dystrophin which cause DMD and BMD 
has revealed some clues regarding the regions of dystrophin most essential to its 
function.  In-frame deletions encompassing both actin-binding domains typically 
cause DMD [34,37,46,186,187].  DMD-causing missense mutations also cluster 
in this region, further emphasizing the importance of the actin binding domains 
for dystrophin’s function [188].  Nonsense mutations resulting in protein 
truncation cause DMD invariably, with the exception of truncations occurring 
distal to the cysteine-rich domain (which may cause BMD), establishing this as 
the distal edge of essential domains for dystrophin function [46,189,190].  
Patients with in-frame deletions of the cysteine-rich domain invariably develop 
DMD [46,190], implicating this region as essential for dystrophin function.  With 
regard to the importance of the rod domain, a particularly informative patient 
study on the structural basis for dystrophin function was carried out by England 
and colleagues who described a BMD family which included an ambulatory 61 
year old man harboring an in-frame deletion of exons 17-48 in the DMD gene, 
resulting in loss in nearly 50% of the coding sequence of dystrophin [45].  This 
deletion was contained entirely within the rod domain, sparing the N-terminal, 
cysteine-rich and C-terminal portions of dystrophin [45].  Collectively, these 
findings in DMD and BMD patients suggest that the actin- and dystroglycan-
binding domains are absolutely essential for dystrophin function, with loss of the 
rod and C-terminal domains having a lesser impact.  A group led by Dr. Jeffrey 
Chamberlain undertook the rational design of truncated mini- and micro-
dystrophin constructs based on the BMD mutation identified by England et al 
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[191,192].  The impetus for these studies was to design functional dystrophin 
constructs compact enough to be packaged into adeno-associated virus (AAV) 
vectors, but also enhanced our understanding of the structural basis for 
dystrophin function.  In these studies, similar to DMD/BMD patients, it was found 
that truncated dystrophin constructs containing dystrophin’s N-terminal actin 
binding domain and cysteine-rich domains can prevent dystrophy in mdx mice 
despite lacking the C-terminal domain and the vast majority of the rod domain 
[191].  Numerous studies have shown these truncated dystrophin constructs to 
be very effective in preventing dystrophy in skeletal and cardiac muscle, 
suggesting that dystrophin’s primary physiological role is related to its function as 
a mechanical tether between actin and β-dystroglycan 
[146,191,192,193,194,195,196,197].   
 In addition to engineered dystrophin constructs, several studies have also 
tested the effects of expressing truncated, but naturally occurring dystrophin 
isoforms on skeletal muscle function.  Expression of the dystrophin isoforms 
Dp116 and Dp71 (which contain the cysteine-rich domain, the C-terminal domain 
and part of the rod domain, and named as Dystrophin protein, molecular weight 
in kDa) did not prevent dystrophy in mdx mice and, in some cases, exacerbated 
muscular dystrophy by displacing utrophin at the sarcolemma 
[198,199,200,201,202].  Expression of Dp260, which retains the rod domain actin 
binding region of dystrophin, partially corrected dystrophy in mdx mice [199].  
Additionally, expression of Dp71 and a truncated dystrophin construct lacking 
only the cysteine-rich domain (and thus expressing the actin binding and 
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dystroglycan binding segments of dystrophin in trans) did not correct dystrophy in 
mdx mice [203].  Collectively, these findings suggest that the ability of dystrophin 
to prevent is directly dependent on its ability to mechanical tether cytoskeletal 
actin to β-dystroglycan.   
 In addition to studies in mdx mice, expression of short dystrophin isoforms 
was also investigated in mice on a wild-type background.  Interestingly, 
expression of short isoforms of dystrophin in wild-type mice caused a dystrophy-
like myopathy [199,201,204].  This was true even for Dp260, which partially 
corrected the phenotype of mdx mice [199].  Additionally, in each case transgenic 
mice showed dystrophic myopathy despite increasing expression of the 
remaining DGC proteins.  This pathological change was associated with loss of 
endogenous dystrophin from the sarcolemma, suggesting that truncated 
dystrophin isoforms can cause dystrophy by exerting dominant negative effect on 
DGC function [199].   
 Dystrophin and the DGC as scaffolds and mediators for cell signaling.  As 
mentioned above, the DGC is associated with numerous proteins involved in cell 
signaling through interactions with dystrobrevin and the syntrophins.  Recently, it 
has also been shown that neuronal nitric oxide synthase (nNOS) can interaction 
directly with dystrophin at spectrin-like repeats 16-17 [205].  Collectively, this has 
led to the hypothesis that dystrophin and the DGC play an important role as 
scaffolds for cell signaling proteins.  A large portion of the research carried out on 
dystrophin’s role in cell signaling has focused on nNOS.  Transgenic 
overexpression of nNOS corrects many histological aspects of dystrophy in mdx 
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mice and reduces serum creatine kinase through mechanisms that are not totally 
clear but may involve suppression of macrophage-mediated inflammation or 
enhanced blood flow to muscle during exercise [206,207].  Additionally, nNOS-
null mice show exaggerated fatigue following exercise and inclusion of the nNOS 
binding domain of dystrophin in micro-dystrophin constructs correct muscle 
circulation and exercise performance in mdx mice [205,208].  However, nNOS-
null mice show no evidence of muscle wasting or sarcolemma permeability and 
crossing these mice onto an mdx background does not enhance muscle wasting 
or sarcolemmal fragility [208,209].  As mentioned above, numerous studies have 
shown that micro-dystrophin proteins lacking the C-terminal domain, which 
therefore cannot recruit dystrobrevin and syntrophins to the sarcolemma, are 
highly effective in preventing muscular dystrophy in mdx mice 
[146,191,192,193,194,195,196,197].  Therefore, whereas the signaling functions 
of the DGC appear to play a role in certain aspects of muscle function, most 
notably exercise capacity and fatigue, they are not necessary for correcting 
muscle wasting, the primary defect of DMD. 
 
Development of dilated cardiomyopathy associated with DMD 
 As discussed above, thorough clinical research has led to a clear 
description of the progressive cardiomyopathy which frequently leads to dilated 
cardiomyopathy in DMD patients [19].  Studies by the Metzger lab and others 
have provided strong evidence that the primary cellular defect leading to necrotic 
cardiac myocyte death and cardiomyopathy in DMD is mechanical destabilization 
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of the membrane in the absence of dystrophin [181,182].   Muscular dystrophy 
caused by loss of other DGC proteins also causes mechanical instability, though 
in some cases it has been shown that apoptosis also contributes to muscle 
wasting [103,105,143,210,211,212].  Although it is tempting to hypothesize that 
necrotic loss of myocytes leads to weakness and dilation of the ventricular wall in 
DMD, it is also important to consider the limitations of studying intact cells and 
the physiological complexities of intact organs.  A gap in knowledge regarding 
DMD cardiomyopathy is a more detailed description of how mechanical instability 
in individual myocytes manifests as dilated cardiomyopathy in DMD patients.  To 
this end, chapter 3 of this thesis investigates the effects of dystrophin loss on the 
mechanical properties of intact hearts to gain a better understanding of the 
mechanisms by which dilated cardiomyopathy develops in DMD patients.  
 
Dystrophin in the pathogenesis of non-inherited heart disease   
 In addition to its involvement in the inherited dystrophinopathies, there is 
also a sizable and expanding body of research to suggest that dystrophin 
expression is significantly altered in various forms of inherited heart disease 
(Table 1-1).  Studies in our laboratory have shown that expression of dystrophin 
declines significantly in aging mice [213].  Additionally, dystrophin expression is 
altered following acute ischemia, enteroviral infection, and isoproterenol-induced 
cardiomyopathy [214,215,216,217,218,219].  In human patients, altered 
dystrophin expression is associated with viral myocarditis, atrial fibrillation, and 
heart failure [220,221,222,223].  Specifically, in these studies, dystrophin is often 
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truncated into smaller fragments as observed by Western blot [215,219,220].  
Additionally, these studies show mislocalization or loss of dystrophin from the 
sarcolemma following injury [214,216,217,218,219,220,221].  Two particularly 
interesting studies carried out by Campos and colleagues and Rodriguez and 
colleagues compared dystrophin to integrins, DGC components, and other 
myocardial proteins following isoproterenol toxicity and ischemia [216,224].   
These studies found dystrophin to have enhanced susceptibility to degradation 
when compared to these other proteins [216,224].  Mechanistically, the manner 
in which dystrophin expressed is diminished in these disease states is not totally 
clear.  There is evidence of age-related declines in dystrophin transcription [225].  
Additionally, dystrophin is a substrate of the calpain proteases [226].  Calpains 
are calcium-dependent cysteine proteases which are aberrantly activated in 
disease processes including DMD and heart failure [124,227,228].  Expression of 
the endogenous calpain inhibitor calpistatin and other calpain inhibitors is 
therapeutic in DMD and heart failure, confirming the maladaptive role of the 
calpains in these disease states [227,229].  However, since the calpains cleave 
numerous substrates the specific effects of dystrophin cleavage remains 
unknown.  Dystrophin is also cleaved by the 2A protease expressed by 
cardiotropic enteroviruses [230].  A detailed discussion of this topic is included 
below in the section entitled, "Dystrophin cleavage and cardiac enteroviral 
infection". 
 The observation that dystrophin expression is altered in non-inherited 
heart disease has led to the provocative hypothesis that dystrophin loss is a 
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common link between inherited and non-inherited heart disease (Table 1-1).    
The importance of cytoskeletal proteins in heart disease is not without 
precedence.  A growing body of research pioneered by Dr. Jeffrey Towbin 
suggests that numerous disease processes converge on disruption of the 
sarcolemma, constituting a “Final Common Pathway” for cardiovascular disease 
[219,231,232,233].  The prospect of dystrophin and other cytoskeletal proteins 
being critical components in non-inherited heart disease pathology is of particular 
relevance given the prevalence of heart disease in the United States.  An age-
related and progressive disease, over 5.5 million Americans suffer from heart 
disease [234].  Additionally, heart failure is the leading cause of death in the 
elderly and the size of the 65+ population is predicted to double in size within the 
next 30 years.  During this time, the total population is predicted to increase by 
only ~30%, suggesting that heart failure will remain at the forefront of clinical 
relevance well into the future (2011 census data).  
 
Dystrophin cleavage and cardiac enteroviral infection 
 Enteroviruses, including the Coxsackie B viruses, are the most common 
cause of viral myocarditis [235].  Cardiac enteroviral infection is a clinically 
relevant condition which is highly variable in its presentation.  Autopsy samples 
taken from apparently healthy individuals show ~5% rate of subclinical 
myocarditis and ~5-10% rate of subclinical enterovirus infection, suggesting 
undiagnosed, asymptomatic viral infection in otherwise healthy individuals 
[236,237,238,239].  Alternatively, patients who succumb to sudden cardiac death 
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show ~20% rate of previously undiagnosed viral infection [240,241].  Similarly, 
~40% of patients with idiopathic dilated cardiomyopathy and those who die 
suddenly following acute myocardial infarction show evidence of undiagnosed 
viral infection [236,242,243,244,245,246,247,248,249].  Acute myocarditis 
brought on by fulminant viral infection clearly plays a role in the pathogenesis of 
many patients [235].  Interestingly, however, it has recently been shown that 5' 
terminal deletions within the coxsackievirus genome can promote stability of the 
viral genome and persistent expression of viral genes within the myocardium 
[250,251].  Collectively, this suggests an insidious mode of cardiomyopathy 
through viral infection and persistent expression of viral genes which promotes 
chronic cardiac disease and development of DCM. 
 Using a computer algorithm, it was found that dystrophin was a predicted 
substrate for cleavage by the 2A protease expressed by enteroviruses (2Apro)  
[252].  A group led by Dr. Kirk Knowlton showed that dystrophin is cleaved by 
2Apro in vitro and that fragmentation of dystrophin was observed following viral 
infection in vivo [230,253].  Importantly, enterovirus infection is also associated 
with increased Evans blue dye uptake, showing membrane permeability and 
suggesting a dystrophic cardiomyopathy [230].  Transgenic expression of 2Apro in 
the heart causes sarcolemmal fragility and the development of dilated 
cardiomyopathy [254].  It has been hypothesized that the ability for 2Apro to 
cleave dystrophin has evolved to increase viral propagation through 
destabilization of the sarcolemma.  This is supported by the finding that mdx 
mice are highly susceptible to enterovirus infection compared to wild-type mice 
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[255].  However, 2Apro also cleaves factors involved in host translation such as 
poly-A binding protein and elongation-initiation factor 4 [230,256,257].  Studies to 
dissect the substrate-specific effects of 2Apro activity in the heart have yet to be 
carried out. 
 As mentioned above, the presence of truncated dystrophin isoforms 
containing dystrophin's dystroglycan-binding function but lacking its actin-binding 
function cause a dystrophic phenotype in skeletal muscle by exerting a dominant 
effect on DGC function [198,199,200,201,202].  Cleavage of dystrophin by 2Apro 
is predicted to result in 2 fragments: an N-terminal fragment containing both of 
dystrophin's actin-binding domains and the majority of the rod domain, and a C-
terminal fragment containing the remainder of the rod domain, the cysteine-rich 
domain, and the C-terminal domain.  Previous studies of dystrophin fragments 
containing dystrophin's actin binding domain have shown that, surprisingly, these 
fragments localize to the sarcolemma, possibly through direct interactions 
between spectrin-like repeat 2 and membrane phospholipids [258,259,260,261].  
Although these N-terminal dystrophin fragments localized to the sarcolemma, 
expression does not exacerbate (or improve) the dystrophic phenotype in mdx 
[260].  This supports the hypothesis that the dominant negative effects of short 
dystrophin isoforms is due to displacement of dystrophin at the DGC through 
competition for β-dystroglycan binding sites.  The putative C-terminal fragment is 
very similar to previously tested short dystrophin isoforms and therefore may also 
exert dominant negative effects when expressed in the heart.  Studies 
investigating the effects of a putative dominant negative dystrophin protein on the 
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heart are lacking, and this would represent a novel mechanism for the 
progression of a clinically relevant disease process.  A characterization of cardiac 
function in transgenic mice expressing the putative products of 2Apro-mediated 
cleavage of dystrophin is the subject of chapter 4 of this thesis. 
 
Major objectives and specific aims 
 The preceding introduction reviews some of the major gaps in knowledge 
regarding the effects of dystrophin deficiency on cardiac function in inherited and 
non-inherited heart disease.  The overarching questions to be answered by this 
work are: (1) How does genetic background affect cardiac function at baseline 
and during physiologically relevant stress in commonly used inbred mouse 
strains?; (2) How does loss of dystrophin affect left ventricular myocardial 
compliance and susceptibility to mechanical injury?; (3) Is expression of the C-
terminal product of dystrophin cleavage by 2Apro sufficient to cause dystrophic 
cardiomyopathy by exerting a dominant negative effect on DGC function?  The 
following specific aims were used to answer these questions. 
 Specific aim 1:  To determine the effect of genetic background on cardiac 
function in several commonly used inbred mouse strains at baseline and during 
stress.  Inbred mouse strains are among the most widely used animal models for 
biomedical research.  Chapter 2 characterizes baseline cardiac function of 8 
commonly used inbred mouse strains using the ex vivo isolated heart preparation 
and in vivo conductance micromanometry.  Inbred strains were also subjected to 
cardiac stressors: ex vivo ischemia and reperfusion for isolated hearts, and 
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esmolol treatment and acute hypoxia while simultaneously recording in vivo 
cardiac function.  
 Specific aim 2: To determine the effects of dystrophin deficiency on the 
mechanical properties of the intact left ventricle.  Previous studies have shown 
that loss of dystrophin affects the mechanical compliance of individual cardiac 
myocytes.  Chapter 3 builds on these studies and characterizes the compliance 
of isolated dystrophin-deficient hearts subjected to mechanical stretch of the left 
ventricle.  Sarcomere length during stretch is also recorded to determine the 
effects of whole-heart stretch on individual cardiac myocytes.  Additional studies 
in other models of inherited muscular dystrophy are also performed to broaden 
the scope of this chapter and identify similarities between discrete forms of 
muscular dystrophy.   
 Specific aim 3: To determine if transgenic expression of the C-terminal 
product of dystrophin cleavage by 2Apro is sufficient to cause dystrophic 
cardiomyopathy.  During enterovirus infection, dystrophin is cleaved by 2Apro into 
a fragment that is structurally similar to non-muscle dystrophin isoforms shown to 
cause dystrophic myopathy by exerting a dominant negative effect on DGC 
function.  Chapter 4 of this thesis characterizes the effects of transgenically 
expressing the products of 2Apro-mediated dystrophin cleavage in the heart.  The 
biochemical and physiological effects of transgene expression on DGC function 
are explored in this chapter.  Dystrophic cardiomyopathy is assessed by 
membrane stability, development of cardiac fibrosis, and susceptibility to 
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ischemic injury.  The results of this study shed light on DGC function in the heart 
and the mechanisms of enterovirus-mediated cardiomyopathy. 
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Tables 
 
Table 1-1.  Proposed mechanisms for non-inherited loss of dystrophin. 
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Figures 
 
Figure 1-1.  The DMD gene and its protein products.  A) Schematic of the 
DMD gene.  Promoters and first introns (with the exception of Dp140, which does 
not have a unique first exon) are indicated by light blue lines and arrows.  Exons 
are indicated by black lines and numbers beneath the gene.  Scale bar – 100 
kbp.  B) Protein products of the DMD gene and their expression.  N-term, N-
terminal domain.  Orange N-terminal domains containing actin binding sites.  
Gray N-terminal domains do not contain actin-binding sites. Hinge domains are 
indicated by red boxes.  Spectrin-like repeats are indicated by blue boxes.  Light 
blue boxes are repeats which participate in actin binding.  Cys-rich, cysteine-rich 
domain.  C-term, C-terminal domain.  Isoforms of DMD named as dystrophin 
protein (Dp) and distinguished from each other by listing the molecular weight (in 
kDa).  
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Figure 1-2.  Schematic of dystrophin and the dystrophin-glycoprotein 
complex (DGC).  Functional domains of dystrophin (A) and the DGC (B).  
Adapted from Barnabei and colleagues [262] with permission from John Wiley 
and Sons. 
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Chapter 2 
 
Influence of genetic background on ex vivo and in vivo cardiac function 
in several commonly used inbred mouse strains1 
 
 
Abstract 
 Inbred mouse strains play a critical role in biomedical research.  Genetic 
homogeneity within inbred strains and their general amenability to genetic 
manipulation has made them an ideal resource for dissecting the physiological 
function(s) of individual genes.  However, the inbreeding that makes inbred mice 
so useful also results in genetic divergence between them.  This genetic 
divergence is often unaccounted for, but may be a confounding factor when 
comparing studies which have utilized distinct inbred strains.  Here, we 
compared the cardiac function of C57BL/6J mice to seven other commonly used 
inbred mouse strains: FVB/NJ, DBA/2J, C3H/HeJ, BALB/cJ, 129X1/SvJ, 
C57BL/10SnJ and 129SvImJ.  The assays used to compare cardiac function 
were the ex vivo isolated Langendorff heart preparation and in vivo real time 
hemodynamic analysis using conductance micromanometry.  We report 
significant strain–dependent differences in cardiac function between C57BL/6J 
                                                 
1 This manuscript was previously published in Physiological Genomics and is copyrighted by the 
American Physiological Society (APS).  It has been reproduced here in accordance with APS 
copyright policy (http://www.the-aps.org/publications/authorinfo/copyright.htm). 
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and other commonly used inbred strains.  C57BL/6J maintained better cardiac 
function than most inbred strains during ex vivo ischemia, particularly when 
compared to 129SvImJ, 129X1/SvJ and C57BL/10SnJ strains.  However, during 
in vivo acute hypoxia 129X1/SvJ and 129SvImJ maintained relatively normal 
cardiac function, whereas C57BL/6J animals showed dramatic cardiac 
decompensation.  Additionally, C3H/HeJ showed rapid and marked cardiac 
decompensation in response to esmolol infusion compared with other strains.  
These findings demonstrate the complexity of genetic divergence between inbred 
strains on cardiac function.  These results may help inform analysis of gene 
ablation or transgenic studies and further demonstrate specific quantitative traits 
that could be useful in discovery of genetic modifiers relevant to cardiac health 
and disease. 
 
Introduction 
For decades biomedical research has relied heavily on the use of inbred 
mouse strains.  The genetic homogeneity within these strains allows for well-
controlled and highly reproducible studies.  Over 450 distinct inbred strains have 
been described in the literature [1], the genomes of numerous commonly used 
inbred strains have been sequenced [2], and the Jackson Laboratory alone 
maintains over 180 inbred mouse strains 
(http://jaxmice.jax.org/list/cat481365.html).  The most common strain of inbred 
mice used in research is the C57BL/6 mouse.  This strain is the most commonly 
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used background of genetically modified mouse strains maintained by the 
Jackson Laboratory (http://jaxmice.jax.org/manual/strains_cataolog.pdf).   
Though not as widely used, other inbred strains have found niches in 
biomedical research due to ease of genetic manipulation or differing propensities 
for developing specific pathologies.  For instance, FVB/N mice are commonly 
used in conventional transgenesis [3] and 129 substrains have been used almost 
exclusively for the isolation of embryonic stem (ES) cells used for gene targeting 
[4,5].  Alternatively, other inbred strains have found use as disease models due 
to naturally occurring mutations in genes linked to human disease [6,7,8,9].  
Even in the absence of engineered or known naturally occurring mutations, 
different inbred mouse strains can vary drastically in their susceptibility to 
clinically relevant diseases.  Previous reports have taken advantage of this 
naturally occurring variation in susceptibility to a particular disease to identify 
quantitative trait loci (QTL) which modify disease pathogenesis [10,11,12,13,14]. 
Cardiovascular disease is the single leading cause of death in the United 
States, affecting approximately 1 in 3 Americans and causing over 800,000 
deaths in 2006 [15].  To effectively investigate the pathological processes 
associated with cardiovascular disease and devise new therapeutic strategies, 
the cardiovascular field has embraced genetically modified inbred mouse strains 
as tools to help understand the fundamental physiological processes governing 
function in the normal and diseased heart.  A survey of the Jackson Labs website 
shows that they maintain over 225 genetically modified mouse lines used for 
cardiovascular research derived from inbred mouse strains.  C57BL/6 is the most 
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common genetic background (Figure 2-1a).  However, mutations are also 
maintained on other common inbred backgrounds as well.  The majority of these 
mice were created using embryonic stem (ES) cells derived from a substrain of 
the 129 inbred strain, then often backcrossed and maintained on a C57BL/6 or 
mixed C57BL/6 x 129 background (Figure 2-1b). 
Several studies have reported strain-dependent differences in 
cardiovascular function between inbred mouse strains by various in vitro and in 
vivo methods [16,17,18,19,20,21].  The majority of these strain-dependent 
differences in cardiac physiology have been carried out on a small subset of 
inbred strains in the absence of disease-related injury/stress.  Previous reports 
have also demonstrated the potent effects of genetic background on modifying 
the cardiac phenotype of genetically modified mice [22,23,24].  For instance, two 
distinct transgenic lines expressing hypertrophic cardiomyopathy-linked mutant 
tropomyosin E108G showed drastically different phenotypes, one displaying 
relatively mild diastolic dysfunction [25] and the other developing overt 
hypertrophic cardiomyopathy and heart failure [26].  Excluding possible 
differences in animal care and housing, the main difference between these 
transgenic mice is their genetic background; one mouse was created on the 
FVB/N background, the other on the C57BL/6 background.  Although the precise 
mechanism underlying this effect is not understood, the phenotypic variation 
between these two transgenic lines contributes to the impetus for this study. 
The purpose of this study was to compare the cardiac function of eight 
commonly used inbred mouse strains at rest and following physiologically 
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relevant stress/injury.  The rationale for conducting these studies is two-fold.  
First, the large number of inbred strains used in medical research necessitates a 
consideration for the physiological differences that arise from genetic divergence 
between strains.  Secondly, the fixed genetic divergence between inbred mouse 
strains serves as a potential substrate for the identification of reproducible 
quantitative traits that differ between inbred strains.  Eight common inbred strains 
were used, six of which are listed on Jackson Laboratory’s list of the most 
popular inbred mouse strains (http://jaxmice.jax.org/findmice/popular.html).  The 
techniques used to measure cardiac function for this study are the Langendorff 
perfused isolated heart preparation and in vivo cardiac hemodynamic function as 
measured by catheter-based conductance micromanometry.  The Langendorff 
preparation is a well established technique for assessing function of a heart 
performing isovolumic contractions at a controlled end diastolic pressure [27,28].  
In vivo hemodynamic analysis provides pressure and volume measurements of 
hearts in the intact animal where physiological loading and autonomic innervation 
remain intact [29].  Additionally, we studied strain-dependent differences in 
cardiac function following physiologically relevant stresses.  Specifically, isolated 
hearts were subjected to ischemia and reperfusion (Day, Nature Med, 2005).  
Mice instrumented for in vivo hemodynamic measurements were subjected to β-
adrenergic blockade and an acute hypoxic challenge.  Strain-dependent 
differences in cardiac function were found both at baseline and following 
physiologically relevant stress.  Collectively, this study highlights strain-
dependent differences between inbred mice which provide insight into marked 
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physiological divergence reported for cardiac transgenic mice generated on 
differing backgrounds.  The identification here of strain-dependent quantitative 
hemodynamic traits may form the foundation of future studies aimed at 
identifying QTL that modify cardiac function.   
 
Materials and Methods 
 Mouse Strains. All mouse strains analyzed in this study were acquired 
from Jackson labs. Mouse strains and stock numbers were as follows: C57BL/6J 
(000664), FVB/NJ (001800), DBA/2J (000671), BALB/cJ (000651), C3H/HeJ 
(000659), 129X1/SvJ (000691), C57BL/10SnJ (000666), and 129S1/SvlmJ 
(002448).  Male mice ages 4-6 months were used in this study. The procedures 
used in this study are in agreement with the guidelines of the University of 
Minnesota and approved by the University of Minnesota Committee on the Use 
and Care of Animals.  
 
 Isolated heart model and ischemia/reperfusion. Ex vivo measurements of 
left ventricular function were carried out as previously described [30].  Mice were 
injected with 300 units sodium heparin and anesthetized with sodium 
pentobarbital.  The heart and lungs were then removed following thoracotomy 
and placed immediately in ice cold Hank’s Buffered Salt Solution without calcium 
and magnesium.  The lungs and thymus were trimmed away to expose the aorta 
which was then cannulated.  Hearts were then perfused at a constant pressure of 
80 mmHg with modified Krebs-Henseleit Buffer (118 mM NaCl, 4.7 mM KCl, 1.2 
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mM MgSO4, 1.2 mM KH2PO4, 10 mM glucose, 25 mM NaHCO3, 2.5 mM CaCl2, 
0.5 mM EDTA) warmed to 37 degrees and brought to pH = 7.4 by bubbling with 
95% 02, 5% CO2.  Hearts were paced at 7 Hz and changes in left ventricular 
pressure were monitored by insertion of a water-filled balloon with an in-line 
pressure transducer into the left ventricle.  Within the left ventricle, the balloon 
was inflated to an end diastolic pressure of 3-8 mmHg.  Following 10-15 minutes 
of stabilization time, hearts were subjected to global no-flow ischemia for 20 
minutes.  Hearts were not paced during ischemia.  Hearts were then reperfused 
for 60 minutes and pacing was reinitiated at 8 minutes following the end of 
ischemia.  Data was collected at a sampling rate of 400 hz and analyzed using 
Chart 6 software (ADInstruments). 
 
 In Vivo Conductance Micromanometry.  Measurements of real time in vivo 
cardiovascular hemodynamics were obtained using conductance 
micromanometry as previously [31,32,33,34].  Mice were anesthetized and 
ventilated via a tracheal cannulation and ventilated via a pressure controlled 
ventilator with 2% isoflurane at a peak inspiratory pressure of 15 cm H2O and a 
respiratory rate of 60 breaths/min. With aid of a dissecting microscope, the heart 
was exposed via a thoracotomy. A 1.4 French Millar pressure-volume catheter 
(PVR-1045; Millar Instruments Inc., Houston, Texas, USA) was then placed into 
the left ventricular chamber via an apical stab.  LV pressure and volume 
measurements were collected at a sampling rate of 1 kHz.  Data were analyzed 
with Ponemah software, P3 Plus (DSI International, St. Paul, MN, USA). 
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Transient inferior vena cava (IVC) occlusions were performed to obtain the end 
systolic and end diastolic pressure-volume relationships.  IVC occlusions were 
performed at baseline and at the end of the esmolol (Brevibloc) infusion. After 
obtaining baseline hemodynamics (ventilated with isoflurane and O2), mice 
received a continuous infusion of esmolol (188 ug/kg/min) for five minutes to 
block all adrenergic responsiveness. After esmolol infusion, mice were infused 
with dobutamine (42 ug/kg/min) to enable recovery of baseline function (Table 2-
1). After dobutamine infusion cardiac function was allowed to return to baseline 
levels. Mice were then exposed to an acute hypoxic challenge (7% O2 balanced 
in nitrogen) and monitored until cardiac pump failure. End-point cardiac 
decompensation was defined as the point when peak LV systolic pressure 
dropped below 60 mmHg. At this point mice were recovered using 100% O2 in 
order to obtain instrument calibration.   
 
 Statistics.   All results are expressed as mean  SEM. Significance was 
established as P < 0.05.  All multivariable assays were assessed using a one 
way analysis of variance (ANOVA) with Dunnets post-hoc test comparing all 
groups to C57BL/6. Survival after the in vivo acute hypoxic challenge was 
assessed by the Fisher exact test.  
 
Results 
 Baseline ex vivo cardiac function.  To quantify strain-specific differences in 
ex vivo cardiac function, hearts from eight inbred mouse strains were isolated 
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and perfused retrograde through the aorta.  To simplify data analysis, all inbred 
strains were compared to the C57BL/6J strain.    In general, baseline ex vivo 
whole heart function of the inbred strains tested was similar to C57BL/6J (Table 
1).  One notable exception was FVB/NJ, which showed significantly higher left 
ventricular developed pressure (LVDP) than C57BL/6J (Table 2-2, P < 0.05).  
Additionally, FVBN/J mice showed significantly higher coronary flow rates than 
C57BL/6J mice at baseline (Table 2-3, P < 0.05).  There were no significant 
differences between C57BL/6J and other inbred strains as measured by the 
maximum derivative of left ventricular pressure, another measure of systolic 
function (Table 2-2).  There were no significant differences in diastolic function at 
baseline between C57BL/6J and other inbred strains as measured by the 
minimum derivative of left ventricular pressure and the rate constant tau (Table 
2-2).  A previous report showed that BALB/c mice have highly variable contractile 
function in the isolated working heart preparation associated inter-animal 
variability in α-skeletal actin expression [35].  However, in our hands the variance 
of left ventricular developed pressure for BALB/cJ mice was statistically similar to 
all other strains by Bartlett’s analysis of variance (data not shown). 
 
 Effects of ischemia and reperfusion on ex vivo cardiac function.  To study 
strain dependent differences in the response to a physiologically relevant stress, 
isolated hearts were subjected to 20 minutes of global ischemia followed by 60 
minutes of reperfusion (Figures 2-2, 2-3).  During reperfusion, three strains 
showed reduced cardiac function compared to C57BL/6J: 129X1/SvJ, 
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129S1/SvImJ, and C57BL/10SnJ.  Each of these strains showed reduced systolic 
function during early (20 minutes) reperfusion compared to C57BL/6J as shown 
by reduced LVDP and % recovery of baseline LVDP (Figure 2-2, 2-3a, P < 0.05).  
Additionally, these strains showed reduced diastolic function compared to 
C57BL/6J as shown by increased LVEDP (Figure 2-2, 2-3a, P < 0.05).  During 
late (60 minutes) reperfusion, 129S1/SvImJ showed reduced systolic function 
compared to C57BL/6J as shown by reduced LVDP and recovery of baseline 
LVDP (Figure 2-2, 2-3b, P < 0.05).  129X1/SvJ showed reduced diastolic function 
compared to C57BL/6J during late reperfusion as shown by increased LVEDP 
(Figures 2-2, 2-3b, P < 0.05).  Additionally, the duration of sustained ventricular 
tachycardia (VTach) during reperfusion was also recorded as a measure of 
ischemic injury [36].  C57BL/6J rarely entered into VTach during reperfusion.  
However, 129X1/SvJ and C57BL/10SnJ entered into VTach for >20 minutes 
during reperfusion (Figure 2-3c, P < 0.05 compared to C57BL/6J).  Because 
VTach generally occurs early in reperfusion, this finding suggests that depressed 
systolic function of 129X1/SvJ and C57BL/10SnJ during early reperfusion is 
caused by increased heart rate as described by the Frank-Starling relationship.  
This is supported by the finding that systolic function of 129X1/SvJ and 
C57BL/10SnJ were similar to C57BL/6J once VTach had resolved during late 
reperfusion.  129SvImJ rarely entered into VTach, suggesting that reduced 
systolic function in these mice was due to reduced contractility following ischemic 
injury.  In addition to 129X1/SvJ, C57BL/10SnJ, and 129S1/SvImJ, several other 
strains showed more subtle differences in cardiac function compared to 
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C57BL/6J during ex vivo ischemia and reperfusion.  These data can be found in 
Figure 2-4. 
 Additionally, to demonstrate the stability and reproducibility of these 
findings, Figure 2-5 shows the results of an initial study carried out with cohorts 
of FVB/NJ, C3H/HeJ and BALB/cJ mice.  As above, isolated hearts from these 
mice were subjected to ex vivo ischemia and reperfusion.  The findings of this 
initial study were comparable with those of the main study, supporting the 
reproducibility  of our findings. 
 
 In Vivo Baseline Hemodynamic Function.  To study differences in real time 
in vivo hemodynamic function between inbred strains, mice were instrumented 
with a 1.4 French Millar conductance micromanometry catheter. This 
methodology allows for precise, real-time assessment of cardiac function by 
simultaneous measurement of left ventricular pressure and volume [29].  There 
were significant differences in systolic and diastolic function between C57BL/6J 
and other strains at baseline, with C57BL/6J generally displaying higher cardiac 
function than the other strains tested (Figure 2-6, Table 2-4).  In measures of 
systolic function, C57BL/6J mice showed increased left ventricular systolic 
pressure (LVSP) compared to FVB/NJ, DBA/2J, BALB/cJ and C3H/HeJ mice, as 
well as increased maximal dP/dt compared to BALB/cJ mice (Figure 2-6, P < 
0.05).  C3H/HeJ mice showed a greater ejection fraction than C57BL/6J.  
However, this may have been a manifestation of smaller cardiac dimensions in 
C3H/HeJ mice as they showed reduced heart weight and maximum volume 
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compared to C57BL/6J mice (Table 2-5, Figure 2-6, P < 0.05).  C57BL/6J mice 
also displayed greater diastolic function compared to other inbred strains, as 
shown by a more negative minimum dP/dt compared to DBA/2J and BALB/cJ 
(Figure 2-6, P < 0.05). 
 
 In Vivo Hemodynamic function during β-adrenergic blockade.  We next 
investigated strain-dependent differences in the effects of adrenergic signaling on 
cardiac function.  Here, in vivo hemodynamic function was recorded during an 
acute infusion of the beta-blocker esmolol.  This manipulation allows the 
dissection of the role of adrenergic signaling in maintaining normal 
cardiovascular performance in different mouse strains. Comparison of the 
response to esmolol infusion revealed strain dependent variation in cardiac 
function during β-blockade (Figure 2-7, Table 2-6).  In the absence of beta-
adrenergic signaling, and similar to baseline in vivo functional measurements, 
C57BL/6J mice maintained higher levels of cardiac function compared to most, 
but not all, of the inbred strains tested (Figure 2-7b).  As described above, there 
were significant differences in cardiac function between inbred strains at 
baseline.  To account for these differences in baseline function when assessing 
the effects of beta-adrenergic blockade on cardiac function, the difference 
between functional parameters at baseline and following 3 minutes of esmolol 
infusion was determined (Figure 2-7c).  Esmolol infusion caused a general 
depression in cardiac function of all strains tested.  However, there were strain-
dependent differences in the degree to beta-blockade depressed cardiac 
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function.  In particular, esmolol infusion had a marked effect on the cardiac 
function of C3H/HeJ mice (Figure 2-7c).  All C3H/HeJ mice underwent severe 
cardiac decompensation within 3 minutes of the start of esmolol infusion as 
shown by greater reductions in LVSP, EF, and maximum dP/dt compared to 
C57BL/6J (Figure 2-7c, P < 0.05).  The effects of beta-blockade were also more 
severe on 129X1/SvJ compared to C57BL/6J as shown by greater reductions in 
maximum dP/dt and LVSP (Figure 2-7c, P < 0.05).  C57BL/10SnJ showed a 
greater decrease in EF compared to C57BL/6J followed esmolol infusion as well 
(Figure 2-7c, P < 0.05).  
 
 In vivo Hemodynamic function during an acute hypoxic challenge.  To 
assess the capacity for inbred mouse strains to respond to an acute cardiac 
stress, mice instrumented with a pressure-volume catheter were exposed to an 
acute hypoxic challenge by ventilation with 7% oxygen [30].  Significant 
differences in cardiac function and survival were observed between C57BL/6J 
and other inbred strains during this challenge (Figure 2-8). To assess cardiac 
function during hypoxia, hemodynamic parameters were compared 6 minutes, 40 
seconds into the hypoxic challenge at which time C57BL/6J mice underwent 
cardiac decompensation as defined in the methods section.  Unlike our findings 
at baseline and during esmolol infusion, C57BL/6J mice showed relatively poor 
cardiac function during an acute hypoxic challenge compared to other inbred 
strains (Figure 2-8b and Table 2-7).  To account for differences in baseline 
function when determining the strain-dependent differences in the response to 
 68 
 
hypoxia, the difference between functional parameters at baseline and following 
acute hypoxia was determined (Figure 2-8c).  Unlike the effects of beta-blockade, 
acute hypoxia had much more severe effects on the cardiac function of 
C57BL/6J mice than most other inbred strains tested.  129X1/SvJ, 129SvImJ and 
FVB/NJ maintained contractility to a greater degree compared to C57BL/6J 
during acute hypoxia as shown by less negative change in LVSP following 
hypoxia (Figure 2-8c, P < 0.05).  Additionally, FVB/NJ, BALB/cJ, 129X1/SvJ and 
129S1/SvImJ showed greater maintenance of EF, SV, and maximum dP/dt 
following hypoxia compared to C57BL/6J (Figure 2-8c, P < 0.05).  FVB/NJ, 
DBA/2J, BALB/cJ, C3H/HeJ, 129X1/SvJ and 129S1/SvImJ showed greater 
maintenance of stroke work following hypoxia compared to C57BL/6J (Figure 2-
8c, P < 0.05).  Analysis of survival during acute hypoxia also emphasizes the 
functional deficit of C57BL/6J mice compared to other inbred strains.  C57BL/6J 
mice showed significantly shorter survival during hypoxia compared to DBA/2J, 
FVB/NJ, C3H/HeJ, BALB/cJ, 129X1/SvJ and 129SvImJ (Figure 2-8c, P < 0.05). 
C57BL/10SnJ was the only strain that did not perform significantly better than 
C57Bl/6J during acute hypoxia.   
 
Discussion 
To our knowledge this is the first detailed comparative analysis of in vivo 
and ex vivo heart performance between several commonly used inbred strains.  
In the past decade, there have been tremendous advances in cardiac biology 
enabled by exquisite cardiac transgenesis and gene targeting studies in mice 
 69 
 
[37,38,39,40,41,42,43].  Cardiac transgenic, knockout and other genetically 
modified mice have been created and backcrossed to a wide array of inbred 
mouse strains, including those tested in this study.  As the number of genetically 
modified mouse models used in cardiovascular research continues to grow, so to 
does the need to identify and appreciate the differences in cardiovascular 
physiology that arise specially from the genetic diversity within these inbred 
mouse strains. 
One main finding of this study is that genetic divergence between 
commonly used inbred mouse strains significantly affects cardiac function.  All 
inbred strains showed functional divergence from C57BL/6J to some degree.  In 
ex vivo preparations, most inbred strains were similar to C57BL/6J which is in 
general agreement with previously published findings on baseline ex vivo cardiac 
function [17].  However, following ischemic injury 129X1/SvJ, C57BL/10SnJ and 
129S1/SvImJ showed significantly reduced cardiac function compared to 
C57BL/6J.  C57BL/10SnJ and 129X1/SvJ showed reduced function that was 
associated with a higher incidence of sustained VTach during the early periods of 
reperfusion compared to C57BL/6J.  This is in agreement with previously 
published findings that isolated C57BL/6 hearts are relatively resistant to 
arrhythmia [44].  This suggests that C57BL/10SnJ and 129S1/SvJ differ from 
C57BL/6J in their propensity for arrhythmogenicity, and not in contractility, 
following ischemic injury.  Conversely, 129S1/SvImJ showed reduced cardiac 
function throughout reperfusion in the absence of VTach, suggesting that 
ischemic injury compromises contractility of these mice without promoting 
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arrhythmia.  In vivo hemodynamic analyses also showed strain-dependent 
differences in cardiac function between C57BL/6J and other inbred strains.  The 
most striking of these was the effect of esmolol on C3H/HeJ mice.  As expected, 
beta-adrenergic blockade reduced cardiac function of all mice to some degree.  
However, esmolol infusion caused severe cardiac decompensation of C3H/HeJ 
within 3 minutes, whereas other inbred strains maintained a reduced, but 
sustainable, level of cardiac function.  Additionally, C57BL/6J mice showed 
greater susceptibility to hypoxia compared to all inbred strains with the exception 
of the closely related C57BL/10SnJ.  This finding under hypoxic challenge is in 
contrast to the majority of findings in this study, where C57BL/6J performed as 
well or better than other inbred strains in cardiac performance tests.  A recently 
published study by Shah and colleagues reported a similar finding when 
comparing the cardiac function of four inbred strains of mice in vivo by 
echocardiography and in vitro by recording sarcomere shortening and 
intracellular calcium handling (CITE SHAH).  Compared to other strains tested 
(BALB/c, C57BL/6 and FVB), 129 mice showed reduced contractility as 
measured by echo but increased calcium handling and sarcomere shortening in 
vitro [45].  Collectively, these findings suggest that the mechanism by which 
cardiac performance is modified by genetic divergence between strains are 
complex and may be governed by specific genetic loci that respond differentially 
to regulate cardiac function depending on the conditions being used to assess 
cardiac function.  
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Although a priori we predicted cardiac function to be similar between in 
vivo and ex vivo preparations, it is not surprising that differences were observed 
given the significant differences between these assays [29,46].  Specifically, the 
absence of physiological loading conditions and autonomic innervation in the ex 
vivo Langendorff preparation are possible reasons for these differences.  
Additionally, these techniques also differ in their methods of anesthesia.  Prior to 
the extraction and perfusion of the heart for ex vivo functional measurements 
mice are anesthetized with pentobarbital.  Pentobarbital is known to depress 
cardiac function in vivo [47,48].  However, once isolated and perfused it is 
generally believed that the effects of pentobarbital are quickly washed out from 
the heart [46].  This is supported by the lack of ex vivo functional differences 
between C57BL/6J and DBA/2J hearts, despite previously published findings that 
DBA mice are highly susceptible to pentobarbital compared to C57BL/6 mice 
[49].  Conversely, during in vivo measurement of cardiac function, mice were 
constantly anesthetized with isoflurane.  Isoflurane has been shown to have 
strain-dependent cardiodepressive effects in vivo [50,51,52,53,54].  Additionally, 
isoflurane anesthesia has been shown to be cardioprotective from ischemic injury 
through mechanisms that are not fully understood, but are thought to mimic 
ischemic preconditioning [55].  Collectively, these previously published findings 
may provide insights to explain the discrepancies in cardiac function between ex 
vivo and in vivo preparations.  Specifically, the cardiodepressive effects of 
isoflurane may differentially affect each inbred strain, confounding our 
comparison of their intrinsic cardiac function.  Additionally, given that isoflurane 
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has been shown to be cardioprotective during ischemia, it stands to reason that 
isoflurane may have a similar effect during hypoxia.  If so, and if the magnitude of 
this effect is strain-dependent, then this may be another mechanism to explain 
the differences between our ex vivo and in vivo findings. 
Our findings of significant differences in cardiac function between inbred 
mouse strains are telling of the impact of genetic divergence between strains on 
cardiovascular physiology.  Although strain-dependent differences in 
physiological function can be challenging when comparing findings of studies in 
which multiple inbred strains have been used, they can also be taken advantage 
of to expand our understanding of complex disease processes.  Similar to 
humans, selected cohorts of mice show distinct susceptibility to specific disease 
processes and these characteristics can be used to inform experimental design.  
For example, when creating a transgenic mouse which expresses a gene thought 
to confer resistance to cardiac ischemic injury, it may be beneficial to create or 
cross this transgenic line to a strain which shows particular susceptibility to 
cardiac ischemic injury such as 129S1/SvImJ as shown here.  Carefully selecting 
the genetic background of novel genetically engineered mice in this way may 
maximize the differences between treated and untreated groups when attempting 
to test a particular therapeutic strategy.  Additionally, because disease therapies 
are designed to treat patients that presumably show increased susceptibility to 
the disease of interest, it makes sense that research studies be designed in a 
similar fashion.   
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Another useful outcome of this study is the identification of quantitative 
traits that arose from the phenotypic diversity between inbred mouse strains.  
Future studies could center on tracking and identification of quantitative trait loci 
(QTL) that modify particular cardiac disease-related physiological processes.  
Previous studies have demonstrated the feasibility of using the genetic 
homogeneity of inbred mouse strains to isolate and identify physiologically 
significant QTL [10,11,12,13,14,22,23].  In this study, we observed significant 
functional differences between inbred strains that were evident when subjected 
to the stresses of ischemia/reperfusion, beta-blockade, and acute hypoxia.  
Because these challenges have direct clinical correlates, we anticipate that future 
studies focused on identifying the QTL to mechanistically explain observed 
functional differences between these strains will be of value.  For example, a 
QTL analysis could be designed with C3H/HeJ and C57BL/6J mice to indentify 
loci that cause the marked loss of function in C3H/HeJ mice following esmolol 
infusion.  Such a study may provide new mechanistic and clinically relevant 
insight into the regulation of cardiac function by β-adrenergic signaling by 
elucidating alterations in this pathway between these strains. This may be 
valuable in identifying factors that alter adrenergic signaling in the normal and 
diseased heart [56,57]. Finally, the finding that under baseline hemodynamic 
testing C57BL/6J mice had improved heart performance compared to other 
strains, including FVB/N, may help explain earlier reports of marked differences 
in mutant transgene outcomes between these inbred strains [25,26].  
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Collectively, the results of this study emphasize the importance of genetic 
divergence between inbred mouse strains and the complex manner in which this 
influences cardiac function.  Additionally, we found that differences in cardiac 
function between inbred strains are modified by both genetic background and the 
physiological test setting (ex vivo/ in vivo) used to assess cardiac function.  
Finally, in this study we have identified numerous quantitative traits that may 
serve as the substrate for future studies on genetic modifiers of cardiac function.  
The demonstration here of reproducible and robust physiological traits, provoked 
under baseline or pathophysiological challenges, should aid future works 
attempting to identify new genetic modifiers of heart performance. 
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Tables 
 
Table 2-1.  Parameters derived just before hypoxia for each strain. Parameters analyzed include end systolic 
pressure (ESp) LV end diastolic pressure (EDp), heart rate (HR), the positive derivative of pressure development (+ 
dP/dt), the negative derivative of pressure development (- dP/dt), tau, maximum LV volume (Vmax), stroke volume (SV), 
ejection fraction (EF), and stroke work (SW). * P < 0.05 vs. baseline values (from Figure 2-6 and Table 2-4) for the same 
strain by t-test. 
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Table 2-2. Baseline functional data for isolated hearts of inbred mouse strains. Systolic function indicated by left 
ventricular end systolic pressure (LVESP), left ventricular developed pressure (LVDP) and the maximum derivative of left 
ventricular pressure (+dP/dt). Diastolic function indicated by left ventricular end diastolic pressure (LVEDP), minimum 
derivative of left ventricular pressure (-dP/dt), and the rate constant tau. All values expressed as mean ± SEM. * = P < 
0.05 compared to C57BL/6J mice. n = 5-8 for each group. 
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Table 2-3. Baseline coronary flow rates and coronary flow rates at 60 minutes reperfusion for inbred strains 
tested. Flow rates were also normalized to average heart weight for each strain. All values expressed as mean ± SEM. 
Normalized body weight = flow rate divided by heart weight. *, **, *** = P < 0.05, 0.01, 0.001 compared to C57BL/6J mice, 
respectively. n = 5-7 for each group. 
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Table 2-4.  Hemodynamic performance at baseline. Parameters include LV end diastolic pressure (LVEDP), preload 
recruitable stroke work (PRSW), stroke volume (SV), and stroke work (SW). All data are mean ± sem. Statistics were 
performed using a 1 way ANOVA with Dunnett’s post hoc analysis comparing each strain to C57BL/6J, * P < 0.05. 
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Table 2-5.  Body weight, tibia length, heart weight and morphometric parameters for inbred strains tested. All 
values expressed as mean ± SEM. *, **, *** = P < 0.05, 0.01, 0.001 compared to C57BL/6J mice, respectively. n = 5-9 for 
each group. 
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Table 2-6. Hemodynamic performance during esmolol infusion. Mean data are shown for cardiac performance at 3 
minutes into the esmolol infusion. Parameters analyzed include LV end diastolic pressure (LVEDP), heart rate (HR), 
maximum LV volume (Vmax), the time constant for isovolumic relaxation (Tau), and stroke work (SW). All data are mean 
± SEM. Statistics were performed using a 1 way ANOVA with Dunnett’s post hoc analysis comparing each strain to 
C57BL/6J, * P < 0.05. 
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Table 2-7. Hemodynamic performance during hypoxia. Mean data are shown for cardiac performance at 6:40 into the 
hypoxic challenge and the delta change from the start of hypoxia (see Table 2-1). Parameters analyzed include LV end 
diastolic pressure (LVEDP), heart rate (HR), the negative derivative of pressure development (-dP/dt), and the maximum 
LV volume (Vmax). All data are mean ± sem. Statistics were performed using a 1 way ANOVA with Dunnett’s post hoc 
analysis comparing each strain to C57BL/6J, * P < 0.05. 
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Figures 
 
Figure 2-1.  Summary of strain background of genetically modified mice 
and ES cells.  a) Genetic background of genetically modified mouse strains 
designed for cardiovascular research maintained at Jackson Labs. b) Genetic 
background of embryonic stem cells used to create genetically modified mouse 
strains maintained at Jackson Labs. 
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Figure 2-2.  Effects of ischemia and reperfusion on isolated hearts of inbred 
mouse strains.  a) Representative compressed pressure tracing from an 
experiment in which an isolated heart was subjected to global ischemia and 
reperfusion.  b) Representative traces from C57BL/6J, 129X1/SvJ, 129S1/SvImJ 
hearts during (1) baseline equilibration, (2) ischemic contracture (at 20 minutes of 
ischemia, just before reperfusion), (3) 20 minutes following initiation of 
reperfusion, (4) 60 minutes following initiation of reperfusion. 
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Figure 2-3.  Ex vivo cardiac function of isolated hearts measured during 
reperfusion. a) Left ventricular developed pressure (LVDP), percent recovery of 
baseline LVDP and left ventricle end diastolic pressure (LVEDP) of isolated 
hearts during early (20 minutes) reperfusion.  b) Left ventricular developed 
pressure (LVDP), percent recovery of baseline LVDP and left ventricle end 
diastolic pressure (LVEDP) of isolated hearts during late (60 minutes) 
reperfusion.  c) Duration of sustained ventricular tachycardia (VTach) during 
reperfusion. Values are expressed as mean ± SEM.  n = 5-8 for each group. * - P 
< 0.05, † - P < 0.01, ‡ - P < 0.01 compared to C57BL/6J. 
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Figure 2-4.  Cardiac performance of isolated hearts measured during global 
ischemia and reperfusion.  For clarity, inbred strains which showed no 
significant differences from C57BL/6J during ischemia and reperfusion are not 
included in these Figures but were included in statistical analysis.  a, b - Systolic 
function quantified by left ventricular developed pressure (LVDP) and the 
maximum derivative of left ventricular pressure (max. dP/dt), respectively.  c, d - 
Diastolic function quantified by the minimum derivative of left ventricular pressure 
(min. dP/dt) and tau, respectively.  Differences from C57BL/6J detected by one-
way ANOVA.  Values are expressed as mean ± SEM.  n = 5-8 for each group.  a-
d - significant differences from C57BL/6J indicated by the following symbols. ‡, ^, 
+, †, * - FVB/NJ, DBA/2J, 129X1/SvJ, C57BL/10SnJ, 129SvImJ, respectively.   
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Figure 2-5.  The reproducibility of ex vivo function measurements.  
Comparison of ex vivo functional data generated from two distinct cohorts of 
FVB/NJ, C3H/HeJ and BALB/cJ isolated hearts carried out several months apart.  
Cohort 1 was a pilot study carried out prior to the larger scale Cohort 2, from 
which all other data presented was generated.  Isolated hearts were subjected to 
global ischemia and reperfusion.  n = 5-7.  * P < 0.05 compared to Cohort 1 by t-
test. 
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Figure 2-6.  Baseline in vivo hemodynamic function of inbred mouse 
strains.  a) Representative raw pressure-volume loops for each strain acquired 
by conductance micromanometry at baseline (PV loops: vertical scale bar: 50 
mmHg; horizontal scale bar: 10 uL). b) Mean data for each strain for various 
cardiac hemodynamic parameters derived from real-time PV analysis. For all 
groups n = 7-9. Values are expressed as mean ± SEM. * P < 0.05 compared to 
C57BL/6J.  
 
 88 
 
 
Figure 2-7.  In vivo hemodynamic function of inbred mouse strains during 
beta-blockade.  a) Representative raw pressure-volume loops for each strain 
acquired by conductance micromanometry after 3 minutes of esmolol infusion 
(PV loops: vertical scale bar: 50 mmHg; horizontal scale bar: 10 uL). b) Absolute 
values for cardiac function during esmolol infusion.  Mean data for each strain for 
various cardiac hemodynamic parameters derived from real-time PV loop 
analysis at 3 minutes following the start of esmolol infusion. c) Representative 
changes in the positive pressure derivative (+dP/dt) during the time course of 
esmolol infusion showing marked differences in adrenergic tone between strains 
(top left).  Mean data for each strain for various cardiac hemodynamic 
parameters derived from real-time PV analysis.  For all groups n = 7-9. Values 
are expressed as mean ± SEM. * P < 0.05 compared to C57BL/6J.  
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Figure 2-8.  In vivo hemodynamic function of inbred mouse strains during 
acute hypoxia.  a) Representative raw pressure-volume loops for each strain 
acquired by conductance micromanometry at 6:40 into the hypoxia challenge (PV 
loops: vertical scale bar: 50 mmHg; horizontal scale bar: 10 uL). b) Absolute 
values for cardiac function during acute hypoxia.  Mean data for each strain for 
various cardiac hemodynamic parameters derived from real-time PV analysis at 
6 minutes, 40 seconds following the start of esmolol infusion.  c) The mean 
change in cardiac function from the start of hypoxia to 6:40 into the hypoxic 
challenge indicating the delta values for given hemodynamic parameters during 
hypoxia compared to baseline.  Mean survival values for each strain during the 
acute hypoxic challenge showing significant differences between groups 
compared to C57BL/6J (bottom right).  For all groups n = 7-9. Values are 
expressed as mean ± SEM. * P < 0.05 compared to C57BL/6J.  
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Chapter 3 
 
Ex vivo stretch reveals altered mechanical properties of isolated 
dystrophin-deficient hearts 
 
 
Abstract 
 Duchenne muscular dystrophy (DMD) is a progressive and fatal disease of 
muscle wasting caused by loss of the cytoskeletal protein dystrophin.  In the 
heart, DMD results in progressive cardiomyopathy and dilation of the left ventricle 
through mechanisms that are not fully understood.  Previous reports have shown 
that loss of dystrophin causes sarcolemmal instability and reduced mechanical 
compliance of isolated cardiac myocytes. To expand upon these findings, here 
we have subjected the left ventricles of dystrophin-deficient mdx hearts to whole-
organ stretch.  Unexpectedly, isolated mdx hearts showed increased left 
ventricular (LV) compliance compared to controls during stretch as LV volume 
was increased above normal end diastolic volume. During LV chamber distention, 
sarcomere lengths increased similarly in mdx and WT hearts despite greater 
excursions in volume of mdx hearts.  This suggests that the mechanical 
properties of the intact heart cannot be modeled as a simple extrapolation of 
findings in single cardiac myocytes.  To explain these findings, a model is 
96 
 
proposed in which disruption of the dystrophin-glycoprotein complex perturbs 
cell-extracellular 
matrix contacts and promotes the apparent slippage of myocytes past each other 
during LV distension.  In comparison, similar increases in LV compliance were 
obtained in isolated hearts from β-sarcoglycan-null and laminin-α2 mutant mice 
but not in dysferlin-null mice, suggesting that increased whole-organ compliance 
in mdx mice is a specific effect of disrupted cell-extracellular matrix contacts and 
not a general consequence of cardiomyopathy via membrane defect processes.  
Collectively, these findings suggest a novel and cell-death independent 
mechanism for the progressive pathological LV dilation that occurs in DMD. 
 
Introduction 
Duchenne muscular dystrophy (DMD) is an inherited disease of 
progressive muscle wasting and is the most common form of muscular dystrophy, 
affecting 1 in 3500 males [1]. The DMD gene resides on the short arm of the X 
chromosome and encodes the protein dystrophin [2,3,4].  Dystrophin is a 427 
kDa cytoskeletal protein and is a member of the dystrophin-glycoprotein complex 
(DGC) in striated muscles [2,5,6].  The DGC is a multimeric protein assembly 
that spans the sarcolemma, tethering the extracellular matrix to the cytoskeletal 
architecture of the cell [7]. Dystrophin is a cytoplasmic component of the DGC 
and plays a crucial role in this trans-sarcolemma linkage, binding cytoplasmic γ-
actin at its N-terminus and the membrane glycoprotein β-dystroglycan at its C-
terminus [8,9,10].  The DGC protein α-dystroglycan interacts with the 
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extracellular matrix by binding laminin in a glycosylation dependent manner 
[7,11].  In the absence of dystrophin, the mechanical rigors of muscle contraction 
are damaging to the sarcolemma.  This mechanical instability has been observed 
in dystrophin-deficient skeletal muscle, which is highly susceptible to lengthening 
contraction-induced sarcolemmal damage and necrotic cell death [12,13].  
Previously, we and have demonstrated similar mechanical instability in isolated 
single cardiac myocytes, by showing that loss of dystrophin causes the formation 
of “micro-tears” in the sarcolemma during passive mechanical distension of 
myocyte [14,15,16].  These sarcolemmal disruptions resulted in increased single-
cell stiffness with eventual hypercontracture and cell death during physiological 
stretch due to unregulated influx of extracellular calcium [15,16]. 
Clinically, DMD is characterized by skeletal muscle weakness and wasting. 
DMD presents early in life and is rapidly progressive, resulting in loss of 
ambulation at approximately 10 years of age and premature death in the early 
twenties [17,18,19,20,21].  Progressive cardiac dysfunction is a significant 
component of DMD which has been observed since the very first descriptions of 
the disease [20,22].  Subclinical cardiac involvement is present in the majority of 
DMD patients in the first decade, the severity of which may be masked by 
significant skeletal muscle dysfunction [20,23,24].In the later stages of DMD, 
nearly all patients show clinically significant cardiac muscle disease [25,26].  
Structurally, the cardiomyopathy of DMD is characterized by fibrosis and 
progressive dilation of the left ventricle (LV), leading to dilated cardiomyopathy 
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(DCM) [26,27].  This frequently progresses to heart failure, which is the primary 
cause of death in at least 20% of DMD patients [20,25]. 
 There are significant gaps in knowledge regarding the progression of 
cardiac involvement in DMD.  Increased myocyte passive stiffness secondary to 
membrane damage in dystrophic myocytes may cause remodeling of LV 
dimensions early in DMD [15].  At present, how dystrophin deficiency causes LV 
dilation as the disease progresses is unclear.  Previous findings regarding the 
progression of DCM in the non-dystrophic heart suggest that progressive LV 
dilation may involve myocyte loss, fibrosis, hypertrophy, and myocyte slippage 
[28,29,30,31,32,33,34].  The degree to which these processes contribute to 
cardiac dysfunction and dilation in DMD is currently unknown. 
In order to build on previous findings in single cardiac myocytes and to 
gain new mechanistic understanding of the effects of mechanical stress on the 
dystrophic heart, we tested the hypothesis that isolated dystrophin-deficient 
hearts have reduced organ level compliance and increased susceptibility to 
mechanical damage.  Using a modified ex vivo isolated heart preparation, results 
show, unexpectedly, that isolated mdx hearts have increased whole-organ 
compliance compared to normal hearts and tolerate considerable LV chamber 
distension without showing evidence of myocyte damage.  To provide further 
mechanistic insight, we tested other genetic models of dystrophy in which either 
the DGC or native membrane repair apparatus were disrupted.  We found that 
defective organ level compliance was evident only when the DGC or its 
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extracellular binding partner laminin were disrupted but not in hearts lacking the 
membrane repair protein dysferlin.   
Collectively, these results provide evidence that disruption of the DGC 
predispose the LV to dilation via apparent myocyte slippage, a novel and cell 
death-independent mechanism for the progressive LV dilation observed in DMD. 
 
Materials and Methods 
 Mice.C57BL/10SnJ (000666), C57BL/10ScSnJ-DMDmdx/J (001801),129-
Dysftm1Kcam/J (006830), 129S1/SvImJ (002448), B6.WK-Lama2dy-2J/J (000524), 
B6.129-Sgcbtm1Kcam/1J (006832) were purchased from the Jackson Labs (Bar 
Harbor, Maine).  Mdx carrier females were created by breeding C57BL/10SnJ 
and C57BL/10ScSnJ-DMDmdx/J mice.  Dystrophin-utrophin double knockout 
(DKO) mice were a kind gift from Dr. Dawn Lowe at the University of Minnesota 
[35].  Mice were used at 8-10 weeks of age, with the exception of DKO mice, 
which were used at 4 weeks due to their severely shortened lifespan. 
 
 Isolated heart preparation.  Mice were anaesthetized with sodium 
pentobarbital and hearts removed via thoracotomy.  Hearts were then 
immediately placed in ice cold modified Krebs-Henseleit buffer (118 mM NaCl, 
4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM glucose, 25 mM NaHCO3, 
2.5 mM CaCl2, 0.5 mM EDTA, 2 mM sodium pyruvate) while the aorta was  
isolated and cannulated.  Hearts were then retrograde-perfused through with 
warm buffer bubbled with 95% O2 and 5% CO2 to maintain a pH of 7.4.  For 
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experiments in non-contracting hearts, isolated hearts were perfused with a 
similar buffer lacking calcium and including the contractile inhibitor 10 mM 2,3–
butanedione monoxime (BDM).The left atrium was then removed and a plastic 
balloon was inserted into the LV.  An in-line pressure transducer allowed for the 
recording of pressures within the LV.  To assess the mechanical compliance of 
isolated hearts, balloons were inflated to a physiological left ventricular end 
diastolic pressure (LVEDP) of 8 mmHg.  Volume required to bring LVEDP to this 
normal range was recorded as Vinit.   
 
 Ex vivo stretch protocol.  To mechanically stretch isolated hearts, volume 
was added in 1 µL increments.  For contracting hearts, 15 µL was added above 
Vinit.  For non-contracting hearts, 30 µL was added above Vinit.  In both 
contracting and non-contracting hearts, the ex vivo stretch protocol was 
performed twice: once to condition the heart and a second time to record 
functional data.  All data reported in this study was taken from the second run 
through the stretch protocol.  Additionally, for this study it was necessary to 
create balloons with significantly larger volumes than the murine LV to ensure 
that pressure developed in the balloon was due to pressure against the LV wall 
and not against the balloon itself. 
 
 Determination of sarcomere length.  To determine sarcomere length at 
given LV pressures, balloons were inflated and clamped to hold LVP at 8, 80 or 
160 mmHg in non-contracting hearts, which were then perfused with 10% zinc-
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formallin and fixed  overnight at 4 degrees Celsius.  The following day, the LV 
free wall was dissected, cut transversely at the mid-wall and embedded in 
paraffin.  Serial 5 μm sections were then cut and mounted on histological slides.  
Immunofluorescence for the Z-disk intermediate filament desmin was then 
performed to visualize sarcomere length.  In brief, sections were dewaxed and 
rehydrated and blocked with 20% normal goat serum for 1 hour at room 
temperature.  Rabbit anti-desmin primary antibody (Novus Biologicals, NB120-
15200) was applied at a 1:300 dilution for 1 hour at room temperature.  After 
washing, goat anti-rabbit IgG-AlexaFluor 594 (Molecular Probes, A-11037) was 
applied for 1 hour at room temperature.  Sections were then washed and 
mounted with Vectashield for visualization.  Slides were visualized using a Zeiss 
LSM510 META confocal microscope (Carl Zeiss). 
 
 Lactate dehydrogenase activity assay.  Perfusates were collected from 
isolated hearts immediately before or after the ex vivo stretch protocol and 
immediately frozen in liquid nitrogen.  5 µL of perfusate was then added to 200 
µL of solution containing 0.12 mM NADH, 2.3 mM pyruvate, and 0.035% BSA in 
100 mM sodium phosphate pH = 7.5.  Absorbance at 340 nm was then 
measured in a plate reader (FLUOstar Omega, BMG Labtech) at 1 minute 
intervals for 15 minutes at a constant temperature of 37 degrees Celsius.  
 
 Statistics.  Comparisons between more than 2 groups were made by one-
way analysis of variance with a Tukey post-test.  When more than one 
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independent variable was tested, two-way analysis of variance with a Bonferroni 
post-test was used to compare groups.  All statistical analysis was carried out 
using Prism (GraphPad Software). 
 
Results 
Previously, we have shown that the sarcolemma of single, membrane 
intact, mdx cardiac myocytes is highly susceptible to passive stretch-induced 
injury leading to increased stiffness, membrane permeability, aberrant 
extracellular calcium influx, and myocyte death [15].  To expand upon these 
findings and determine how single-cell mechanics manifest at the whole-organ 
level, the effects of mechanical stretch on the left ventricular chamber of WT and 
mdx hearts were determined (Figure 3-1). 
Mechanical compliance of intact, beating mdx hearts.  To determine 
whole-organ cardiac compliance wild-type (WT, C57BL/10SnJ) and mdx hearts 
were isolated, perfused, and subjected to mechanical stretch using a water filled 
plastic balloon placed within the LV chamber.  WT and mdx mice used in this 
study were of similar age (65 ± 0.9 vs. 67 ± 1.8 days, n = 14-16, P> 0.05), had 
similar body weights (27.1 ± 0.4 vs. 27.4 ± 0.9 grams, n = 14-16, P> 0.05) and 
heart weights (176.4 mg ± 5.4 vs. 158.8 ± 10.3 milligrams, n = 5, P> 0.05).  
Miniature plastic balloons were first inflated and set at standard physiological LV 
end diastolic pressure (LVEDP) of 6-8 mmHg [15,36].  Baseline LV 
hemodynamic performance of mdx and WT hearts was similar (Table 3-1).  In 
order to estimate the LV volume of isolated hearts at standard LVEDP, the 
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volume required to reach LVEDP of 8 mmHg was recorded (Vinit, Figure 3-1c).  In 
agreement with previously published findings, we found that mdx hearts have 
reduced LV volumes at normal LVEDP [15].  To assess whole-organ compliance 
in isolated hearts, 15 µL was added to the balloon in the LV chamber in 1 µL 
increments while simultaneously recording LV pressure.  Unexpectedly, as 
volume was added above Vinit  mdx hearts showed a blunted increase in LVEDP 
indicating an increase in whole-organ compliance compared to WT hearts 
(representative tracings shown in Figure 3-1a,b).  This blunted increase in 
LVEDP as LV volume increased above Vinit is quantified in Figure 3-1d by two-
way ANOVA, showing significant main effects of strain, volume and an 
interaction of the two.  To account for differences in Vinit between WT and mdx, 
changes in LVEDP during stretch were also plotted against %Vinit.  Similar results 
were observed when plotting the results this way despite the smaller Vinit of mdx 
hearts, further accentuating the enhanced whole-organ compliance of mdx hearts 
(Figure 3-1e). To visualize the true LV EDP-volume relationship, LVEDP was 
plotted against LV volume (Vinit + volume added during stretch protocol, Figure 3-
1f).  Here, mdx hearts initially showed a left-shifted LVEDP-volume curve 
compared to WT at lower volumes.  As LV volume was increased, the blunted 
slope of the LVEDP-LV volume relationship in mdx hearts approached that of WT 
mice (Figure 3-1f).  Collectively, these results demonstrate the increased 
compliance of isolated mdx hearts compared to WT. 
Because we have previously shown that LV dimensions are normalized in 
mdx mice upon application of membrane sealant poloxamer 188 in vivo[15], we 
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conducted parallel studies in isolated hearts perfused with buffer containing P188. 
Inclusion of P188 did not affect the increase in LVEDP as volume was added 
above Vinit in isolated mdx hearts, suggesting that the alteration in mechanical 
properties we observe are not related to mechanical instability of the sarcolemma 
(Figure 3-2a, b). 
To determine if the observed differences in whole-organ compliance were 
due to mechanical injury of the heart or to ischemia caused by high LV pressures, 
we recorded the flow rate of perfusate through the coronary vasculature.  
Throughout the ex vivo stretch protocol there was no difference in coronary flow 
between mdx and WT hearts (Figure 3-2c).  Additionally, to determine if the 
observed differences in whole-organ compliance were due to mechanical injury 
of mdx hearts during the stretch protocol, we assessed lactate dehydrogenase 
(LDH) activity in perfusates from isolated hearts before and after stretch.  WT 
and mdx hearts showed similar initial perfusate LDH activity and showed no 
increase in perfusate LDH activity following stretch (Figure 3-2d).  All values for 
LDH activity recorded for hearts used in the stretch protocol were less than those 
recorded following ischemia/reperfusion injury, suggesting that minimal cell injury 
or death occurred during the stretch protocol.  Additionally, isolated hearts 
recovered cardiac performance to pre-stretch levels following the ex vivo stretch 
protocol (Figure 3-1a, b and Figure 3-2e).  Collectively, these findings are 
evidence that the stretch protocol used in this study causes minimal injury to 
isolated hearts and had negligible effects on cardiac function. 
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To further characterize the effects of altered dystrophin expression on the 
mechanical properties of the myocardium, isolated hearts of mdx carrier females 
were subjected to the LV chamber stretch protocol.  In these mice, 50% of 
cardiac myocytes lack dystrophin due to random X inactivation [37].  Isolated 
hearts of mdx carrier females showed whole-organ compliance similar to WT 
hearts (Figure 3-1d, g). We also assessed the whole-organ compliance of hearts 
from the dystrophin/utrophin double knockout (DKO) mouse.  Utrophin is a 
homolog of dystrophin which is upregulated in mdx mice, compensating for 
dystrophin loss and contributing to a relatively mild phenotype compared to DMD 
patients [35,38,39].  DKO mice have a severe dystrophic phenotype which is 
similar to DMD patients [35,38,39].  DKO mice showed increased compliance 
compared to both WT and mdx mice (Figure 3-1d, h). DKO mice were used at 4 
weeks of age in this study due to their severe dystrophic phenotype and had 
smaller LV volumes (Figure 3-1c).  Because similar volumes were introduced to 
all hearts regardless of Vinit, smaller hearts would be predicted to show greater 
increases in LVEDP as LV volume is increased Vinit if compliance were equivalent.  
Whole-heart compliance was reduced in DKO mice compared to controls despite 
this smaller initial volume.  Additionally, the sarcomeric protein titin is a central 
determinant of passive compliance in cardiac muscle [40,41].  Alternative splicing 
of titin early in life and may contribute to altered cardiac compliance as the heart 
develops [42].  However, in the mouse, the adult isoforms of titin are predominant 
after day 5 [42]. 
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 Effects of altering perfusate calcium on mechanical properties of isolated 
dystrophic and WT hearts. To determine the effects of altering extracellular 
calcium concentrations on the mechanical properties of the myocardium, isolated 
hearts were perfused with a modified Kreb’s buffer containing high (3 mM) 
calcium or low (1.75 mM) calcium (all solutions contained 0.5 mM EDTA).  
Similar to our findings under standard conditions (2.5 mM calcium + 0.5 mM 
EDTA) isolated mdx hearts perfused with high and low calcium showed a similar 
blunted increase in LVEDP as volume was increased above Vinit as compared to 
controls (Figure 3-3a, b).  To further characterize the effects of altering 
extracellular calcium on myocardial compliance, hearts were perfused with buffer 
lacking calcium and containing 10 mM 2, 3-butanedione monoxime to inhibit 
excitation-contraction coupling.  Perfusion with this solution halted all contractile 
activity of isolated hearts.  Non-contracting hearts were then subjected to 
mechanical stretch by adding 30 μL to the heart in 1 μL increments as above.  
Similar to our findings in beating hearts, non-contracting mdx hearts showed 
increased whole-organ compliance compared to WT, as shown by a blunted 
increase in LVEDP as LV volume increased (Figure 3-3c).  This is alternatively 
quantified in Figure 3-3d as the volume required to raise LVEDP to a given value.  
Statistical analysis by two-way ANOVA shows significant main effects for strain, 
volume, and an interaction of the two, indicating that mdx hearts require 
significantly greater volume to raise LVEDP to 60, 80, 100, and 120 mmHg 
(Figure 3-3d).  The congruence of our findings in contracting and non-contracting 
hearts suggests that, in contrast to individual myocytes, the altered whole-organ 
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compliance of mdx hearts is not due to calcium-dependent processes such as 
sarcomeric contraction or trans-sarcolemmal influx of extracellular calcium[15]. 
 The use of non-contracting hearts also allowed for quantitative 
assessment of diastolic sarcomere lengths at a set LVEDP.  This analysis is 
confounded in contracting hearts due to obligatory contraction-induced changes 
in sarcomere length.  Accordingly, we measured sarcomere length at a range of 
set LV pressures to determine the single-cell manifestations of whole-organ 
stretch in non-contracting WT and mdx hearts.  Non-contracting hearts were 
perfusion-fixed at LVEDP pressures of 8, 80, or 160 mmHg.  Immunofluorescent 
staining for desmin was then used to visualize and measure average sarcomere 
lengths of the mid-LV free wall (Figure 3-4a).  At each LV pressure tested, mdx 
and WT hearts had similar sarcomere lengths (Figure 3-4b).  Given that mdx 
hearts require significantly larger volumes to increase LVP from 8 mmHg to 60, 
80, 100, and 120 mmHg (Figure 3-3d), this suggests altered stretch at the level 
of individual myocytes did not contribute to increased whole-organ compliance in 
mdx hearts. 
 
 Whole-organ heart compliance in other genetic models of muscular 
dystrophy.  Based on the findings above, we hypothesized that increased whole-
organ compliance observed in mdx hearts is due to disruption of DGC-mediated 
connectivity between the extracellular matrix and the intracellular architecture of 
the cell.  To test this hypothesis, we determined the whole-organ compliance of 
other mouse models of muscular dystrophy in which the DGC or its binding 
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partners are disrupted: β-sarcoglycan-null mice and dy2j mice.  β-sarcoglycan is a 
DGC protein normally expressed in the heart, the lack of which causes Limb-
Girdle Muscular Dystrophy Type 2E [43,44]. Dy2j mice carry a mutation in the 
LAMA2 gene which causes abnormal splicing of the laminin-α2 transcript and 
expression of a truncated protein [45].  The α2 heavy chain subunit of the 
extracellular matrix protein laminin is bound by α-dystroglycan, facilitating the 
interaction of the DGC with the extracellular matrix. [46].  Mutations in LAMA2 
cause merosin-deficient muscular dystrophy [47].Similar to mdx mice, the hearts 
of both β-sarcoglycan null and dy2j hearts showed smaller LV volumes at normal 
LVEDP and increased whole-organ compliance compared to WT hearts (Figure 
3-5a, b, e).  Here, similar to mdx mice, we observed increased compliance 
despite smaller Vinit for β-sarcoglycan null and dy2j hearts (Figure 3-5).  To 
determine if the observed effects on compliance in mdx, dy2j, and β-sarcoglycan-
null hearts are due to specific effects on the DGC or other effects of membrane 
dysfunction in muscular dystrophy, we also performed the stretch protocol on 
dysferlin-null hearts.  Dysferlin is a membrane repair protein which is not 
associated with the DGC, the lack of which causes Limb Girdle Muscular 
Dystrophy Type 2B [48].  These mice have no defect in expression of DGC 
proteins [49].  Results showed no differences in LV volumes or whole-organ 
compliance of dysferlin-null and WT hearts (Figure 3-5c, d, e).  Collectively, the 
findings of altered whole-organ compliance in β-sarcoglycan null and dy2Jhearts, 
but not in dysferlin-null hearts, support the hypothesis that specific disruption of 
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the cytoskeleton-DGC-extracellular matrix alters the mechanical properties of the 
myocardium and increases whole-organ compliance. 
 
Discussion 
 The main new finding of this study is that whole-organ compliance is 
increased in mdx mice and in other genetic models of muscular dystrophy 
involving DGC disruption, but not in a model of dystrophy caused by membrane 
repair dysfunction.  These results suggest that the DGC is a central determinant 
of organ-level mechanical compliance of the heart.  This, in conjunction with our 
findings of similar changes in sarcomere length despite significantly greater 
excursions in LV volume lead us to speculate that side-to-side translation of 
myoyctes past each other (myocyte slippage) accounts for the increased 
compliance observed in mdx, dy2J and β-sarcoglycan-null hearts. 
 Numerous studies have shown that loss of dystrophin alters the response 
of striated muscle to mechanical stress.  In skeletal muscle, loss of dystrophin 
alters passive mechanical properties and increases susceptibility to mechanical 
injury [50,51,52].  In cardiac tissue, we and others have previously shown that 
dystrophin deficient cardiac myocytes are highly susceptible to mechanical injury 
and show increased passive stiffness [14,15,16].  Here we have subjected 
isolated hearts to mechanical distension to determine the effects of dystrophin 
loss on whole-organ compliance and susceptibility to mechanical damage.  In 
contrast to individual cardiac myocytes, isolated mdx hearts show increased 
compliance compared to normal tissue as LV chamber volume is increased.  This 
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defect is exacerbated in dystrophin/utrophin double knockout hearts and fully 
prevented in mdx carrier females expressing dystrophin in only 50% of cardiac 
myocytes. During the distension protocol mdx hearts underwent significant 
expansion of the LV with no significant effects on cardiac function, membrane 
damage or cell death.  Given the stiffness and mechanical fragility of individual 
mdx cardiac myocytes during passive stretch [14,15], this suggested that factors 
other than mechanical instability of the membrane contribute to the increased 
whole-organ compliance of mdx isolated hearts. This is further supported by the 
finding that the altered compliance of mdx hearts was not corrected by P188.  In 
a previous report Wilding and colleagues performed ex vivo stretch and showed 
no difference between isolated mdx and WT hearts in LV volumes as LVEDP 
was increased up to 30 mmHg [53].Our findings are in agreement with this study 
since we show no significant difference in LVEDP between mdx and WT as 
volume is increased within this range (Figure 3-1d).  However, here we have 
conducted a more exhaustive analysis of the pressure-volume relationship to 
reveal significant differences compared to WT. 
To determine possible mechanisms for the observed changes in the 
mechanical properties of isolated hearts, perfusate calcium concentrations were 
altered.  Increasing, decreasing, or removing calcium altogether did not alter the 
enhanced compliance mdx hearts.  This is evidence that neither trans-
sarcolemmal calcium entry through membrane “micro-tears” nor sarcomeric 
contraction contributes to the increased compliance of mdx hearts.  Additionally, 
since α-dystroglycan binding to laminin is dependent on calcium [7], the 
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persistence of increased compliance in mdx hearts in the absence of calcium 
suggests that secondary alterations in non-DGC proteins may contribute to 
apparent myocyte slippage in DMD.  Although it was not investigated in the 
current study, caveolin-3, which is upregulated in mdx mice[54], interacts with the 
DGC and numerous cell signaling molecules[55,56], and participates in buffering 
mechanical membrane stress [57], may contribute to the altered mechanical 
properties of the mdx myocardium. 
To determine the effects of whole-organ stretch on individual myocytes in 
WT and mdx hearts, we determined sarcomere length at a given LV pressure in 
non-contracting hearts.  Sarcomere lengths were similar at all LV pressures 
tested despite the considerably larger volumes required to alter LV volume in 
mdx hearts, suggesting that enhanced stretch of the myocytes does not account 
for increased compliance in isolated mdx hearts.  Since alterations in LV volume 
expansion are not strictly tracked by proportional changes in sarcomere length, 
this indicates the mechanical properties of the dystrophic myocardium are not a 
simple extrapolation of findings from isolated cells. To explain these findings, we 
propose a model for the accelerated pathological dilation of the ventricle in DMD 
where disruption of the DGC promotes side-to-side myocyte slippage during 
whole-organ stretch (Figure 3-6). Specifically, we propose that as isolated mdx 
hearts are stretched, loss of dystrophin and disruption of the DGC causes 
myocytes to translate past each other to a greater degree than occurs in normal 
hearts.  Therefore, in this model, enhanced compliance in mdx isolated hearts is 
primarily due to disruptions in the cytoskeleton-DGC-extracellular matrix axis. 
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Additional experiments in β-sarcoglycan-null, dy2J, and dysferlin-null mice are 
consistent with our hypothesis that disruption of the DGC-mediated linkage of 
cells with the extracellular matrix promotes enhanced whole-organ cardiac 
compliance.  Collectively, these findings suggest a mechanism for the increased 
whole-organ compliance of mdx isolated hearts which is independent of 
sarcolemma instability and single myocyte compliance.  In the broader context of 
pathophysiological processes associated in DMD cardiomyopathy, the findings 
presented here suggest a novel mechanism for the pathological ventricular 
dilation that occurs in DMD and highlight the complex physiological interactions 
that should be considered when studying diseases at the whole-organ level. 
 When formulating the working model for the increase compliance of 
dystrophic hearts observed here, we have also considered other possible 
explanations for our findings.  Specifically, previous reports have shown that 
chronic ventricular dilation is associated with alterations in the collagen I/collagen 
III content, promoting a more compliant ventricular wall [58,59,60].  However, the 
tight-skin mouse which expresses a ~20% excess of collagen in the heart shows 
no abnormalities in passive ventricular compliance [61]and mdx mice typically 
show no significant deposition of collagen within the myocardium at the ages 
tested in this study [62].  Additionally, the sarcomeric protein titin has previously 
been shown to be truncated in skeletal muscle of DMD patients [41,63,64].  
However, our lab has previously shown that permeabilized cardiac myocytes 
from the golden retriever muscular dystrophy dog show no difference in passive 
compliance over a wide range of sarcomere lengths, suggesting that loss of 
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dystrophin does not alter the compliance of the contractile machinery within 
cardiac myocytes [14].  Previous reports have highlighted the complex 
arrangement of myocytes in the LV, the anisotropic mechanical properties of the 
myocardium, and how layers of cardiac myocytes may shear past one another 
during stretch [65,66,67].  Although our model is consistent with the data 
reported, we cannot exclude that the observed increase in compliance of 
dystrophic hearts is due to cardiac myocyte rearrangement, perhaps through 
shear along myocardial cleavage planes, or altered myocyte orientation within 
the LV.  Additionally, we as shown in Figures 3-1 and 3-5, the initial LV volumes 
varied between strains, with some dystrophic strains showing significantly 
smaller LV volumes compared to controls.  In this study we have assumed that 
the observed differences in LV geometry will not significantly affect our 
measurement of compliance. 
Although LV dilation is associated with numerous disease states of the 
heart, the basis for this pathological change in organ structure is not well 
understood.  Previous studies suggest that myocyte slippage contributes to LV 
dilation in numerous disease states including aortic stenosis, acute and chronic 
myocardial infarction, and end-stage dilated cardiomyopathy [31,68,69,70,71,72].  
Specifically, these studies have shown that pathological dilation of the LV is 
associated with LV free wall thinning and reductions in transmural cell number 
which are not accounted for by hypertrophy, myocyte lengthening or fibrosis 
[31,68,69,70,72].  Ultrastructural analysis of the chronically dilated LV has shown 
that pathological LV dilation is associated with disruption of normal sarcolemmal 
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registry in a dog model of DCM, suggesting myocyte slippage [71].  These 
findings, along with other reports of disrupted DGC expression in cardiomyopathy 
brought on by enteroviral infection [73,74], ischemia [75,76], acute isoproterenol 
toxicity [77], or in idiopathic dilated cardiomyopathy [75,76] lead us to speculate 
that DGC-mediated changes in whole-heart compliance may be a common 
pathway to pathological LV dilation in numerous forms of cardiac disease.  
Additionally, the mice used in this study were at an early stage in the progressive 
cardiomyopathy of mdx mice and typically show minimal evidence of 
histopathology [62].  Therefore, it is possible that the observed changes in whole-
organ compliance in mdx hearts are an initiating event in the remodeling of the 
dystrophin deficient myocardium. Future studies aimed at determining the age-
related changes in cardiac compliance of mdx mice may be useful for 
understanding the progression of cardiomyopathy in DMD.  
 With regard to the relevance of the findings presented here to the 
pathogenesis of heart disease in DMD, there are limitations of this study that 
need to be considered.  The retrograde perfused isolated heart preparation used 
in this study is a well-established and widely used technique for assessing whole-
organ cardiac function as measured during isovolumic contraction and 
relaxation[78,79].  However, this technique does not faithfully recapitulate the 
mechanical rigors of contraction and relaxation due to lack of physiological 
loading conditions [79].  Previous reports have shown that cardiac function of the 
dystrophin deficient heart suffers greatly under conditions of physiological loading 
[80,81].  Although this is certainly a limitation of this study, the absence of 
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physiological loading allowed us to isolate and study mechanical properties of the 
intact dystrophin deficient heart independent of myocardial damage caused by 
physiological loading conditions.  We assert that, in addition to the effects of 
myocyte damage and loss due to mechanical instability of the membrane, the 
dystrophin deficient heart exhibits a heightened propensity to undergo myocyte 
slippage which contributes to the progressive pathological dilation of the ventricle 
in DMD.  In addition to this limitation, when using our ex vivo stretch protocol we 
observed differences in whole-organ compliance between WT and mdx hearts at 
LVEDP well above the normal physiological range.  We speculate that the 
processes resulting in increased compliance in isolated hearts at high LVEDP 
may also occur under normal conditions in vivo, but at a much slower rate.  This 
is in line with the slowly progressive dilation that occurs over the course of years 
in DMD [25,26].  Additionally, our model of myocyte slippage at high LVEDP is in 
agreement with previous findings showing that while the sarcomeric filament and 
disregulgated calcium handling influences the mechanical properties of the 
myocardium at lower sarcomere lengths, extracellular matrix proteins contribute 
significantly at higher sarcomere lengths [15,82,83].  Increased compliance in 
dystrophic hearts was only seen at increased sarcomere lengths, suggesting that 
these defects were cause by altered extracellular matrix interactions. 
 In addition to our findings in mdx hearts, we also found similar 
disturbances in the whole-organ mechanical properties of β-sarcoglycan-null and 
dy2J hearts.  Mutations in β-sarcoglycan and laminin-α2 cause muscular 
dystrophy and, importantly, dilated cardiomyopathy[45,84,85,86,87].  However, 
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there is evidence from previous studies in skeletal muscle to suggest divergence 
in the mechanisms by which these mutations cause disease when compared to 
mdx mice.  β-sarcoglycan-null mice show muscle wasting and increased 
membrane permeability [84].  It is not known if β-sarcoglycan-null mice show 
enhanced susceptibility to contraction-induced injury, but previous studies have 
shown significant divergence in susceptibility to contraction-induced injury in 
genetic models of sarcoglycan deficiency [88,89,90].  Dy2J mice show muscle 
wasting but no evidence of membrane permeability or susceptibility to 
contraction-induced injury [91,92].  Expression of the anti-apoptotic protein BCL2 
corrects muscle defects in laminin deficient mice but not mdx mice, suggesting 
that aberrant apoptosis plays a role in the pathology of these mice [93].  Despite 
these differences in the mechanisms of muscle wasting in mdx, dy2J, and β-
sarcoglycan-null mice, each of these models shows enhanced whole-heart 
compliance.  We speculate that these mouse models share the phenotype of 
increased whole-heart compliance due to disruptions of cell-extracellular matrix 
interactions.  Genetic ablation of β-sarcoglycan weakens the interaction of α-
dystroglycan with the DGC [87] and the mutant laminin-α2 heavy chain expressed 
by dy2J mice is defective in its ability to form stable polymers[94], suggesting 
mechanisms for the disruption of the contacts between myocytes and the 
basement membrane.  Collectively, the finding of altered mechanical properties 
in the hearts of mdx, β-sarcoglycan-null and dy2J mice suggests that altering cell-
extracellular matrix contacts may be a common mechanism for pathological 
dilation of the heart in diseases which alter cell-extracellular matrix interactions 
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by a variety of different mechanisms.  The lack of mechanical defects in the 
hearts of dysferlin-null mice further supports this hypothesis.  Mutations in 
dysferlin cause muscular dystrophy, but development of dilated cardiomyopathy 
is rare[95,96].  Since dysferlin is not known to directly participate in cell-cell or 
cell-matrix contacts, the finding of normal compliance in dysferlin-null hearts 
supports the hypothesis that changes in whole-organ mechanical compliance are 
specifically caused by disruptions in the cell-extracellular matrix axis of 
connectivity. The findings presented in this study may therefore have relevance 
for other disease processes which involve pathological cardiac dilation. 
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Tables 
 LVDP LVEDP dP/dt max. dP/dt min.
C57BL/10SnJ 134.2 ± 2.9 6.9 ± 0.1 4936 ± 162 -3708 ± 137
mdx 133.7 ± 2.7 7.1 ± 0.3 4929 ± 123 -3339 ± 140
 
Table 3-1.  Baseline ex vivo functional data for isolated WT and mdx hearts.  
Contractile function as shown by LV developed pressure (LVDP) and the 
maximum derivatives of LV pressure (dP/dt max.) were similar between groups.  
Lusitropic function as measured by LV end diastolic pressure (LVEDP) and the 
minimum derivative of LV pressure (dP/dt min.) were also similar between the 
groups by student’s t-test.  n = 12-15. 
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Figures 
 
Figure 3-1.  Response of isolated, contracting dystrophic isolated hearts to 
ex vivo stretch.  A, B) Compressed representative pressure tracings from 
WT(A) and mdx (B) hearts during ex vivo stretch protocol.  Inset: uncompressed 
pressure tracings from mdx and WT hearts prior to stretch, vertical scale bar = 50 
mmHg, horizontal scale bar = 1/7 sec.  C) Volume required to reach 8 mmHg 
EDP within the LV (Vinit).  D) Altered whole-organ compliance of mdx  and DKO 
hearts as shown by plotting LVEDP against volume added above Vinit during ex 
vivo stretch.  Mdx carrier females show normal whole-organ compliance.  E) 
Differences in compliance of mdx and WT hearts are further exaggerated when 
plotting the %Vinit versus LVEDP.  F) Estimation of the true LV volume-EDP 
relationship based on data from 1C and 1D.  Balloon only controls are shown to 
prove that recorded changes in pressure were not due to overfilled balloon.  G) 
Whole-organ compliance of isolated WT and mdx carrier female hearts shown as 
the LV volume versus LVEDP.  H) Whole-organ compliance of isolated mdx and 
DKO hearts shown as LV volume versus LVEDP.     n = 5-14.  For C, * - P < 0.05 
by t-test.  For D, * - p < 0.05  for C57BL/10SnJ vs. DKO, ^ - P < 0.05 for 
C57BL/10SnJ vs. mdx, † - p < 0.05 for mdx versus DKO by two-way ANOVA with 
main effects for strain, volume, and an interaction of the two. 
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Figure 3-2.  P188 does not affect whole-organ compliance and ex vivo 
stretch does not cause ischemia or impair cardiac function.  A) Whole-organ 
compliance of isolated mdx hearts with and without poloxamer 188 in the 
perfusate (mdx data is same data used in figure 1).  B) Vinit of mdx perfused with 
and without poloxamer 188 perfusate (mdx data is same data used in figure 1).  
C) Rate of perfusate flow through the coronary vasculature in mdx and WT 
hearts during ex vivo stretch protocol.  D) LDH activity in perfusates from WT and 
mdx hearts taken before and after ex vivo stretch protocol.  E) Comparison of 
LVDP before and after ex vivo stretch protocol.  No significant differences 
between observed between WT and mdx mice by two-way ANOVA.  For A, B, n 
= 7-14.  For C, n = 11-14.  For D, n = 5-9.  For E, n =8-12.* - p < 0.05 vs. all other 
groups by one-way ANOVA. 
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Figure 3-3.  Response of non-contracting WT and mdx hearts to altered 
perfusate calcium.  A, B) Altered compliance in mdx hearts as shown by plotting 
LVEDP against volume added above Vinit during ex vivo stretch when perfused 
with 2.5 (A) or 1.25 mM (B) Ca2+.  C) Increased compliance in non-contracting 
hearts perfused with BDM and without calcium during stretch as shown by 
plotting LVEDP against volume added above Vinit.  D) Quantification of altered 
compliance in mdx hearts, plotted as volume required to raise LVP from 8 mmHg 
(Vinit) to 20, 40, 60, 80, 100, or 120 mmHg.  E) Volume required to reach 8 mmHg 
EDP within the LV (Vinit).  n = 5-10. * - p < 0.05 by two-way ANOVA with main 
effects for strain, volume, and an interaction of the two. 
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Figure 3-4.  Quantification of changes in sarcomere length during whole-
organ stretch in non-contracting hearts.  A) Representative image of desmin 
stained section of fixed heart tissue.  Average sarcomere length of 
circumferentially oriented myocytes from the mid LV free wall was determined.  
Scale bar = 50 µm.  B) Quantitation of average sarcomere length at a range of 
fixed LV pressures.  n = 5-10.  No significant differences were detected by two-
way ANOVA. 
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Figure 3-5.  Whole-organ passive compliance of isolated hearts of other 
models of muscular dystrophy.  A) Left, altered compliance of β-sarcoglycan-
null and dy2J hearts as shown by plotting LVEDP against volume added above 
Vinit during ex vivo stretch.  Right, estimation of the true LV volume-EDP 
relationship, plotted as in figure 1F.  B) Left, normal compliance of dysferlin-null 
hearts as shown by plotting LVEDP against volume added above Vinit during ex 
vivo stretch.  Right, estimation of the true LV volume-EDP relationship.  n = 5-7. * 
- p < 0.05 for dy2J versus C57BL/6, ^ - p < 0.05 for β-sarcoglycan-null versus 
C57BL/6.  Statistical comparisons made by two-way ANOVA with main effects for 
strain, volume, and an interaction of the two. 
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Figure 3-6.  Proposed model for the mechanical properties of the 
dystrophic myocardium.  Top, model for the increased stiffness of mdx 
myocytes.  Stretch causes membrane permeability and influx of extracellular 
calcium, leading to unregulated contraction (indicated in red).  Bottom, model for 
the effects of dystrophin expression on myocardial compliance.  In mdx hearts, 
membrane permeability may initially cause contraction of LV volume at normal 
LVEDP, resulting in a left shift in the LV volume-EDP curve.  As volume is 
increased, loss of dystrophin leads to increased slippage of myocytes past one 
another, leading to increased compliance.  This is corrected by expression of 
dystrophin in 50% of myocytes in mdx carrier females. 
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Chapter 4 
 
The C-terminal fragment of dystrophin cleavage by enteroviral protease 2A 
causes dystrophic cardiomyopathy  
 
 
 
Abstract 
 Cardiac enterovirus (EV) infection is a clinically relevant disease state 
which causes cardiomyopathy and heightened susceptibility to ischemic injury.  
Previously, it has been shown that dystrophin is targeted for cleavage by the 2A 
protease (2Apro) expressed by enteroviruses.  This has led to the hypothesis that 
dystrophin cleavage contributes to the cardiomyopathy of EV infection.  However, 
because 2Apro cleaves numerous substrates, it is unclear if dystrophin contributes 
to cardiomyopathy during EV infection or is a byproduct of other pathological 
processes.  To address this question, transgenic mice were created expressing 
the N- and C-terminal products of 2Apro-mediated dystrophin cleavage (NtermDys 
and CtermDys, respectively).  CtermDys transgenic mice show a dystrophic 
cardiomyopathy as shown by enhanced Evans blue dye (EBD) uptake during 
isoproterenol stress, enhanced myocardial fibrosis, and increased susceptibility 
to ischemic injury.  CtermDys transgenic mice also show ~70% reduction in 
expression of dystrophin along with a ~5-10 fold increase in other DGC proteins.  
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Conversely, NtermDys transgenic mice show no dystrophic cardiomyopathy as 
indicated by normal EBD uptake during isoproterenol stress and express normal 
levels of dystrophin and other DGC proteins.  To more accurately simulate EV 
infection, double transgenic mice were generated which also show a dystrophic 
cardiomyopathy as shown by EBD uptake during isoproterenol stress that is 
similar to CtermDys mice.  Collectively, these results show that expression of 
CtermDys is sufficient to cause a dystrophic cardiomyopathy with the NtermDys 
protein having no detrimental effects.  These findings provide evidence that 
CtermDys acts as a dominant negative to DGC function and, therefore, could 
contribute significantly to the cardiomyopathy of EV infection. 
 
Introduction 
 Cardiotropic enterovirus (EV) infection is a clinically relevant disease 
process associated with numerous forms of cardiac dysfunction.  Cardiac EV 
infection varies greatly in its clinical presentation.  Interestingly, 5-10% of healthy, 
asymptomatic individuals show evidence of EV infection in the heart [1,2].  
However, EV infection is also the most common cause of acute myocarditis [3] 
which can manifest as mild cardiomyopathy as well as in sudden and 
catastrophic loss of heart pump function [4].  EV infection has been detected in 
20-40% of patients who die suddenly following acute myocardial infarction and 
40% of patients with apparently idiopathic dilated cardiomyopathy [1,5,6,7,8,9].  
Collectively, these findings suggest that EV infection increases the susceptibility 
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of the heart to injury and dysfunction.  However, the mechanisms by which EV 
compromises cardiac function are not totally clear.   
 Dystrophin is a cytoskeletal protein encoded by the Duchenne muscular 
dystrophy (DMD) gene.  Genetic mutations leading to loss of dystrophin cause 
DMD.  Dystrophin exists as a cytoplasmic constituent of the dystrophin-
glycoprotein complex (DGC) [10,11].  The DGC is a multimeric, sarcolemma-
spanning protein complex which provides a mechanical linkage between the 
cytoskeleton and the extracellular matrix [12].  Dystrophin participates in this 
linkage by binding cortical actin at its N-terminus and the DGC protein β-
dystroglycan at its C-terminus [13,14,15,16].  Loss of dystrophin causes 
mechanical fragility of the sarcolemma, leading to muscle necrosis and wasting 
in skeletal and cardiac muscle [17,18,19,20,21,22].  Previously, it has been 
shown that the 2A protease (2Apro) expressed by the coxsackieviruses cleaves 
dystrophin within its hinge 3 domain in vitro [23,24].  Additional studies have 
shown that EV infection causes truncation of dystrophin into fragments consistent 
with 2Apro cleavage in vivo, and that transgenic expression of 2Apro causes 
cardiomyopathy [23,25].  This has led to the hypothesis that cleavage of 
dystrophin is a causal mechanism for the pathogenesis of cardiac EV infection.  
However, in addition to dystrophin, 2Apro also cleaves numerous other substrates 
including poly-A binding protein, eIF-4G and serum response factor [26,27,28].  
Therefore, the specific contribution of 2Apro-mediated dystrophin cleavage to the 
cardiomyopathy of EV infection is unclear. 
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 In addition to loss of full-length dystrophin, the presence of cleaved 
fragments of dystrophin following EV infection suggests an alternative 
mechanism for the cardiomyopathy of EV infection.  Previously, it has been 
shown that expression of truncated non-muscle isoforms of dystrophin in skeletal 
muscle cause dystrophic myopathy by acting in a dominant negative manner to 
dystrophin [29,30,31,32,33,34].  These isoforms, derived from alternative 
promoters within the DMD gene, retain dystrophin's C-terminal β-dystroglycan 
binding domain but lack some or all of dystrophin’s actin binding domains (Figure 
4-1).  The putative products of dystrophin cleavage by 2Apro are an N-terminal 
fragment containing dystrophin's actin binding domains and a C-terminal 
fragment containing dystrophin's β-dystroglycan binding domain (Figure 4-1).  
Because this C-terminal dystrophin fragment is very similar to the previously 
described dominant negative isoforms of dystrophin, we hypothesize that the 
presence of this fragment is sufficient to cause dystrophic cardiomyopathy in the 
heart.  Additionally, because enterovirus infection has been associated with 
increased risk of death following acute myocardial infarction [1], we also 
hypothesized that expression of the C-terminal fragment of dystrophin cleavage 
by 2Apro promotes susceptibility to ischemic injury.  To test these hypotheses, we 
transgenically expressed the N-terminal and C-terminal products of dystrophin 
cleavage by 2Apro in independent lines.  The C-terminal dystrophin fragment 
localizes to the sarcolemma and causes a significant reduction in expression of 
full-length dystrophin.  Transgenic expression of the C-terminal dystrophin 
fragment also causes membrane instability, myocardial fibrosis, and reduced 
137 
recovery of heart pump function following ischemic injury.  The N-terminal 
fragment of dystrophin cleavage by 2Apro was found at the sarcolemma and, 
surprisingly, in the nucleus of cardiac myocytes.  Expression of this fragment 
neither affected levels of endogenous dystrophin nor caused disruption of 
membrane stability.  Collectively, these results show that expression of the C-
terminal product of dystrophin cleavage by 2Apro is sufficient to cause dystrophic 
cardiomyopathy and increase susceptibility to ischemic injury by exerting a 
dominant negative effect of DGC function.  
 
Materials and Methods 
 Generation of transgenic mice.  The NtermDys and CtermDys transgenic 
constructs were PCR cloned from the murine dystrophin cDNA containing an N-
terminal flag tag (a kind gift from Dr. James Ervasti).  For the NtermDys 
transgene, the forward primer 5'-ttttttttgcggccgctacggcaaggtgctgtgcacggatctgccc-
3' and reverse primer 5'-ttttttttgcggccgccctgaccgtgcccctggactgagcactact-3' were 
used to generate a 7.3 kbp product with flanking NotI restriction sites.  For the 
CtermDys transgene, the forward primer 5'-
ttttttttgcggccgcgagcagaacgtgatctcggaggaggacctgggagcctctgccagtcagactgttactcta-
3' and reverse primer 5'-ttttttttgcggccgcactgaaactaaggactccatcgctctgccc were 
used to generate a 3.9 kbp product with flanking NotI restriction sites.  PCR 
mutagenesis was also used to add an N-terminal myc tag to the CtermDys 
transgene.  These transgenic constructs were then inserted into a transgenic 
vector with expression dictated by the cardiac specific α-myosin heavy chain 
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promoter [35].  These constructs were then injected into (C57BL/6 X SJL)F2 
mouse eggs and potential founders were screened for the transgene by PCR.   
 
 Animals.  Transgenic mice were backcrossed onto the C57BL/10SnJ 
genetic background for 2-3 generations (Jackson Labs, 000666).  Care was 
taken to monitor the hypomorphic dysferlin allele inherited from SJL mice, which 
was bred out of mice used in this study.  Mice of 2-3 months of age were 
analyzed, with the exception of mice used for histological analyses which were 
aged to 6 months.  To generate transgenic (mdx) mice, male transgenic mice 
were bred with mdx females (Jackson Labs, #001801).  Transgenic male pups 
from these crosses were then used for experiments. 
 
 Total protein extraction.  Total cellular protein was extracted using a 
protocol modified from Bunnell and colleagues [36].  Briefly, hearts were frozen in 
liquid then pulverized and resuspended in 1% SDS, 5 mM EGTA, and protease 
inhibitors.  Samples were boiled for 2 minutes then centrifuged at 14,000 g for 2 
minutes and the supernatant was collected.  Protein concentration was 
determined using a BCA protein assay kit (Thermo Scientific). 
 
 Membrane protein isolation. Hearts were prepared as described 
previously [37].  Briefly, hearts were similarly frozen in liquid nitrogen, pulverized 
and resuspended in a buffer solution lacking detergent, and centrifuged at 14,000 
g for 25 minutes.  The supernatant was collected and centrifuged at 100,000 g 
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for 40 minutes.  The pellet resulting from this spin was then resuspended in 
buffer containing 0.6 M KCl and washed for 1 hour at 4 degrees Celsius.  
Samples were then centrifuged at 150,000 g for 40 minutes and the resultant 
pellet was resuspended in a Tris-Sucrose buffer.  Protein concentration was 
determined using a BCA protein assay kit (Thermo Scientific). 
 
 Western blotting.  50 µg of protein was loaded per sample in 4-20% Tris-
HCl gels for SDS-PAGE (Bio-Rad).  Protein was then transferred to nitrocellulose 
or PVDF membranes.  Membranes were blocked in 5% nonfat dry milk in TBS-T 
and primary antibodies were applied for 1 hour at room temperature:  Primary 
antibodies: rabbit anti-dystrophin (C-terminal, Abcam, ab15277, 1:1000); mouse 
anti-dystrophin (mid-rod, millipore, mab1692, 1:200), mouse anti-α-dystroglycan 
(Millipore, 05-593, 1:1000), rabbit anti-desmin (Novus Biologicals, NB120-15200, 
1:1000), mouse anti-myc (Cell Signaling Technology, 2276, 1:1000), mouse anti-
flag (Sigma, F1804, 1:500), mouse anti-α-sarcoglycan (Vector Labs, VP-A105, 
1:100), mouse anti-γ-sarcoglycan (Vector Labs, VP-G803, 1:100), mouse anti-β-
dystroglycan (Vector Labs, VP-B205, 1:100),.  Secondary antibodies were then 
applied for 1 hour at room temperature and blots were imaged using an Odyssey 
Infrared Scanner (LiCor)  
 
 Immunofluorescence.  Hearts of transgenic mice were embedded in OCT 
and sectioned.  Heart sections were fixed in 3% formaldehyde for 15 minutes at 
room temperature, then washed in PBS and blocked in 5% normal goat serum + 
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0.3% Triton X-100 in PBS for 1 hour at room temperature.  Sections were then 
incubated with primary antibodies in 1% BSA + 0.3% Triton X-100 in PBS 
overnight at 4 degrees Celsius.  Primary antibodies: Rabbit anti-Laminin (Sigma, 
L9393. 1:500), mouse anti-myc (Cell Signaling Technology, 2276, 1:500), mouse 
anti-dystrophin (Millipore, mab1692, 1:50).  Sections were then washed and 
incubated with secondary antibodies in 1% BSA + 0.3% Triton X-100 in PBS for 1 
hour at room temperature.  Sections were washed in PBS and mounted using 
Vectashield mounting media with DAPI (Vector Laboratories).  Slides were 
visualized using Zeiss LSM510 META confocal microscope (Carl Zeiss). 
 
 Evans blue dye uptake.  Membrane permeability was assessed using a 
technique adapted from Bostick and colleagues [38].  Mice were given 
intraperitoneal injections of Evans Blue Dye in PBS at a dose of 200 μg/g body 
weight.  18 hours later, mice were given 3 injections of isoproterenol at a dose of 
500 ng/g body weight at 18, 20, and 22 hours post-Evans blue dye injection.  
Mice were then euthanized at 24 hours post-Evans blue dye injection.  Hearts 
were then cut into 3 sections across their short axis and frozen in OCT.  Percent 
Evans blue positive area from thin sections of these samples was quantified 
using ImageJ (National Institutes of Health).  For each heart, the Evans blue 
positive area reported is an average of 3 cross sections. Sections were imaged 
on a Zeiss Axio Observer Z1 inverted microscope.  Mosaic images were created 
with AxioVision 4.7 (Carl Zeiss). 
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 Histological Analysis.  Hearts of 6 month old mice were taken and 
embedded in OCT or fixed in 10% formalin overnight and embedded in paraffin.  
Hearts were then sectioned and stained with Sirius Red and Fast Green to detect 
collagen deposition within the myocardium.  Sections were imaged on a Zeiss 
Axio Observer Z1 inverted microscope.  Mosaic images were created with 
AxioVision 4.7 (Carl Zeiss). 
 
 Isolated heart preparation. Mice were injected with 300 units sodium 
heparin and anesthetized with sodium pentobarbital. The heart and lungs were 
then removed following thoracotomy and placed immediately in ice-cold Krebs-
Henseleit buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
10 mM glucose, 25 mM NaHCO3, 2.5 mM CaCl2, 0.5 mM EDTA). The lungs and 
thymus were trimmed away to expose the aorta, which was then cannulated. 
Hearts were then perfused at a constant pressure of 80 mmHg with Krebs-
Henseleit buffer warmed to 37°C and brought to pH = 7.4 by bubbling with 95% 
02, 5% CO2. Hearts were paced at 7 Hz, and changes in left ventricular pressure 
were monitored by insertion of a water-filled balloon with an in-line pressure 
transducer into the left ventricle. Within the left ventricle, the balloon was inflated 
to an end diastolic pressure of 3-8 mmHg. Following 10–15 min of stabilization 
time, hearts were subjected to global no-flow ischemia for 20 min. Hearts were 
not paced during ischemia. Hearts were then reperfused for 60 min, and pacing 
was reinitiated at 8 min following the end of ischemia. Data were collected at a 
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sampling rate of 400 Hz and analyzed using Chart 6 software (ADInstruments) 
[39]. 
 
 Statistics. Comparisons between 2 groups were made using students t-
test.  When more than 2 groups were being compared, one-way analysis of 
variance was used with a Tukey post-test.  All statistical analysis was carried out 
using Prism (GraphPad Software). 
 
Results 
 Characterizing transgene expression.  Transgenic mice were created 
expressing either the N-terminal or C-terminal product of dystrophin cleavage by 
2Apro specifically in the heart.   
 The N-terminal transgene encoded protein (NtermDys) has a predicted 
molecular weight of 283 kDa and consists of an N-terminal flag epitope tag and 
the first 2426 amino acids of dystrophin.  This includes the N-terminal domain of 
dystrophin and the N-terminal portion of the central rod domain (including 
spectrin-like repeats 1 through 19 and hinges 1, 2, and part of hinge 3, see 
Figure 4-1a).  Thus, this fragment retains both the N-terminal and rod domain 
actin binding regions of dystrophin [40,41].  Previous reports have shown that 
inclusion of an N-terminal flag epitope tag does not impair dystrophin’s actin 
binding function [42,43,44]. Western blot of total protein extracts from several 
lines of transgenic mice were performed to assess transgene expression.  The 
NtermDys transgene was detected using an anti-flag antibody as well as an anti-
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dystrophin antibody (recognizing amino acids 1181-1388 of dystrophin, present 
in both dystrophin and the NtermDys transgene).  Four transgenic lines were 
chosen for further study (lines 368, 367, 10, 13) which exhibited a range of 
transgene expression (Figure 4-1b).   
 The C-terminal transgene (CtermDys) has a predicted molecular weight of 
145 kDa and consists of an N-terminal myc tag and the last 1251 amino acids of 
dystrophin.  This includes dystrophin's cysteine-rich domain, C-terminal domain, 
and C-terminal portion of the rod domain (containing part of hinge 3, hinge 4, and 
spectrin-like repeats 20-24, see Figure 4-1).  Thus, this transgene retains 
dystrophin's dystroglycan binding and C-terminal scaffolding regions.  For this 
transgene, only two lines of transgenic mice were obtained that bred 
successfully.  Western blot of total protein extracts were carried out to assess 
transgene expression.  The CtermDys protein was detected using an anti-myc 
antibody as well as an anti-dystrophin antibody (recognizing amino acids 3661-
3677 of dystrophin, present in both dystrophin and the CtermDys transgene).  No 
significant difference was detected in expression of the CtermDys transgene 
between transgenic lines 1 and 4 (Figure 4-1c).  Line 4 was chosen for further 
study due to ease of breeding. 
 
 Expression of DGC proteins in transgenic mice.  In total protein extracts, it 
was noted that expression of dystrophin was normal in NtermDys transgenic 
mice, but reduced in CtermDys transgenic mice (Figure 4-1c).  To determine if 
expression of DGC proteins at the membrane is altered in transgenic mice, 
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Western blots for DGC proteins were performed on KCl-washed microsomes.  
Quantitatively, expression of dystrophin, α-dystroglycan, α-sarcoglycan, β-
dystroglycan, and γ-sarcoglycan in NtermDys transgenic mice was similar to non-
transgenic mice by Western blot (Figure 4-2a-e,).   
 Similar to findings in total protein extracts, dystrophin expression at the 
membrane was significantly reduced in CtermDys transgenic mice to 
approximately 30% of normal levels (Figure 4-2a).  Expression of α-dystroglycan, 
α-sarcoglycan, β-dystroglycan, and γ-sarcoglycan was significantly increased 
(~5-10 fold) in CtermDys transgenic mice by Western blot (Figure 4-2b-e).   
 
 Subcellular localization of the NtermDys transgene.  The subcellular 
localization of the NtermDys transgene was assessed by immunofluorescence on 
heart sections of NtermDys transgenic mice.  NtermDys transgenic mice (line 
368) were crossed onto the dystrophin-deficient mdx genetic background.  An 
anti-dystrophin (mid-rod) antibody was used to show subcellular localization of 
the NtermDys transgene while also using an anti-laminin antibody to 
simultaneously show the sarcolemma.  The NtermDys transgene localized to the 
sarcolemma, similar to dystrophin, but was also found more diffusely throughout 
cardiac myocytes in a striated pattern (Figure 4-3b, d, f).  Surprisingly, the 
NtermDys transgene also appeared to be present in the nucleus of cardiac 
myocytes as illustrated by colocalization with DAPI (Figure 4-4).  The NtermDys 
transgene appears only in the nuclei of cardiac myocytes, and not in the nuclei of 
other cells within the heart (Figure 4-4h).  Immunoflourescence was also used to 
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show normal expression of the DGC protein β-dystroglycan was normal in 
NtermDys(mdx) hearts (Figure 4-3g, h). 
 
 Subcellular localization of the CtermDys transgene.  Subcellular 
localization of the CtermDys transgene was determined by immunofluorescence 
on heart sections from CtermDys transgenic mice.  Localization of the CtermDys 
transgene was determined using an anti-myc antibody while using an anti-laminin 
antibody to visualize the sarcolemma.  The CtermDys transgene localized at or 
near the sarcolemma, similar to dystrophin (Figure 4-5b, d, f).  In agreement with 
our quantitative assessment of DGC protein expression, CtermDys mice also 
showed increased expression of β-dystroglycan at the membrane (Figure 4-5g, 
h).  
 
 Sarcolemmal stability in transgenic mice.  Previous reports have shown 
that transgenic expression of non-muscle isoforms of dystrophin that bind 
dystroglycan but not actin cause dystrophic myopathy in skeletal muscle by 
acting as a dominant negative to dystrophin [29,33,34].  The non-muscle 
isoforms that show a dominant negative effect are structurally similar to the 
CtermDys protein.  Thus, to determine if expression of the NtermDys or 
CtermDys transgenes causes dystrophic cardiomyopathy as shown by 
mechanical instability of the sarcolemma, Evans blue dye (EBD) uptake was 
measured with isoproterenol stress (see Materials and Methods).  Non-
transgenic mice show EBD uptake in only a few scattered cardiac myocytes 
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during this stress (Figure 4-6b).  The four NtermDys transgenic lines showed 
similar EBD uptake to non-transgenic mice during isoproterenol stress (Figure 4-
6).  In contrast, CtermDys transgenic mice showed significantly enhanced EBD 
uptake compared to non-transgenic mice which appeared as focal areas of 
membrane instability (Figure 4-6a, g).  EBD uptake in CtermDys mice was similar 
to the dystrophin-deficient mdx mouse, which showed significantly enhanced 
EBD uptake compared to non-transgenic mice (Figure 4-6a, i).   
Since cleavage of dystrophin by 2Apro results in both N- and C-terminal 
cleavage products, CtermDys (line 4) mice were crossed to NtermDys (line 368) 
mice to create double transgenic (DTg) mice.  DTg mice show EBD uptake 
during isoproterenol stress that is significantly greater than non-transgenic mice 
but similar to mdx and CtermDys transgenic mice (Figure 4-6a, h).  Collectively, 
these results show that expression of CtermDys, but not NtermDys, is sufficient 
to cause sarcolemmal instability and dystrophic cardiomyopathy. 
 Previous reports have shown that, in addition to causing dystrophic 
myopathy in normal skeletal muscle, some non-muscle isoforms of dystrophin 
which lack all actin binding functionality also exacerbate the already dystrophic 
phenotype of the mdx mouse and is thought to contribute to their mild phenotype 
compared to DMD patients [32,33,34].  This occurs through competition with 
utrophin, which is upregulated in mdx mice [32,45].  To determine if the 
CtermDys transgene can similarly compete with utrophin for binding to β-
dystroglycan in mdx mice, the CtermDys transgene was bred onto the mdx 
genetic background and membrane stability was assessed by EBD uptake during 
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isoproterenol stress.  CtermDys(mdx) mice showed no signficant difference in 
EBD uptake in CtermDys (mdx) mice compared with mdx mice (Figure 4-6a, k)1.  
The NtermDys (line 368) transgene was also crossed onto the mdx genetic 
background and sarcolemmal stability was similarly tested.  EBD uptake in 
NtermDys(mdx) was elevated compared to non-transgenic mice, but similar to 
mdx mice (Figure 4-6a, j).  Collectively, these results show that the NtermDys 
transgene does not further impair sarcolemma stability in mdx mice.  Additionally, 
these results show a non-significant trend towards sarcolemmal instability in 
CtermDys(mdx) mice compared to mdx mice which warrants further study. 
 
 Histological evidence of cardiomyopathy in transgenic mice.  Mdx mice 
show progressive histopathology within the myocardium as seen by inflammation 
and fibrosis [18].  To determine if similar processes occur in our transgenic mice, 
heart sections from NtermDys, CtermDys, non-transgenic littermates, and mdx 
mice were stained with Sirius Red to visualize collagen deposition in the 
myocardium.  At 6 months of age, non-transgenic and NtermDys mice show very 
little evidence of fibrosis in the myocardium (Figure 4-7a-d).  Conversely, aged 
mdx and CtermDys mice show large focal regions of fibrosis within the 
myocardium which may result from remodeling due to focal cardiac myocyte 
damage observed by EBD uptake (Figure 4-7e-h).  These results suggest that 
CtermDys transgenic mice show histological pathology comparable to that 
observed in dystrophic cardiomyopathy.  
                                                 
1 This is a nascent data set with n = 4 for Cterm(mdx) mice.  Currently, we observe a non-
significant trend towards greater EBD uptake in Cterm(mdx) mice.  Further studies are in 
progress to determine if this is a physiologically significant difference. 
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 Enhanced susceptibility to ischemic injury in CtermDys transgenic mice.  A 
previous study has shown that EV infection predisposes human patients to death 
following acute myocardial infarction [1].  The mechanism by which EV infection 
increases susceptibility to ischemic injury is not fully understood but given that 
CtermDys mice show dystrophic cardiomyopathy, we hypothesized that presence 
of the CtermDys transgene would increase susceptibility to ischemic injury.  To 
test this hypothesis, hearts of CtermDys and non-transgenic littermate controls 
were isolated, perfused, and subjected to 20 minutes of ischemia and 60 minutes 
of reperfusion.  Prior to ischemia, non-transgenic and CtermDys transgenic 
hearts showed similar systolic function as measured by left ventricular developed 
pressure (LVDP, Figure 4-8a).  However, recovery of systolic function during 
reperfusion was significantly impaired in CtermDys hearts (Figure 4-8a, e).  
Additionally, recovery of diastolic function during reperfusion was also 
significantly impaired in CtermDys hearts as shown by elevated left ventricular 
end diastolic pressures (LVEDP, Figure 4-8b, e).  These results show that 
expression of the CtermDys transgene enhances susceptibility of the heart to 
ischemic injury. 
 As mentioned above, previous studies have shown that non-muscle 
dystrophin isoforms that can bind dystroglycan but not actin exacerbate the 
dystrophic phenotype of mdx mice through competition with utrophin for binding 
of β-dystroglycan.  To determine if expression of the CtermDys transgene 
enhances susceptibility to ischemic injury in mdx mice, isolated hearts of 
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CtermDys(mdx) and non-transgenic mdx littermate controls we subjected to 
ischemia and reperfusion injury.  Mdx hearts were more susceptible to ischemic 
injury than wild-type heart as shown by impaired recovery of LVDP and LVEDP 
during reperfusion (Figure 4-8c, d, e).  CtermDys(mdx) hearts showed recovery 
of LVDP and LVEDP during reperfusion which was impaired when compared 
with non-transgenic mice, but was similar to mdx mice (Figure 4-8c, d, e)2.  
However, because the ischemia/reperfusion protocol used here causes severe 
injury in mdx mice with very little recovery of function during reperfusion, future 
studies with a more mild ischemic injury may be useful in detecting a 
physiologically significant difference in recovery from ischemia between mdx and 
CtermDys(mdx) mice.  Collectively, these findings suggest that expression of the 
CtermDys transgene does not dramatically alter susceptibility of mdx mice to 
ischemic injury.  However, future studies with a less severe ischemia protocol are 
required to determine if the CtermDys transgene alters recovery of cardiac 
function following ischemia in a physiologically meaningful way. 
 
Discussion 
 Previous reports have shown that the C-terminal fragment of dystrophin 
cleavage 2Apro is structurally similar to those previously described as exerting a 
dominant negative effect on DGC function [23,24].  Based on these findings, we 
hypothesized that expression of the C-terminal product of 2Apro-mediated 
dystrophin cleavage would cause dystrophic cardiomyopathy through competition 
                                                 
2 Here again, sample size is small for CtermDys(mdx) mice, with n = 3.  Ongoing studies are 
aimed at increasing the size of this group to augment our ability to detect physiologically relevant 
differences in cardiac function. 
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with dystrophin.   This study has directly tested this hypothesis by expressing 
both the N- and C-terminal products of dystrophin cleavage by 2Apro.  We found 
that the C-terminal product of dystrophin cleavage by 2Apro localizes to the 
sarcolemma and causes dystrophic cardiomyopathy as shown by sarcolemmal 
instability, cardiac fibrosis, and increased susceptibility to ischemic injury.  
Conversely, the N-terminal product of dystrophin cleavage by 2Apro did not affect 
sarcolemmal stability or cause cardiomyopathy.  Collectively, these results show 
that the C-terminal product of dystrophin cleavage by 2Apro is sufficient to cause 
dystrophic cardiomyopathy.  We hypothesize that this cardiomyopathy is due to 
CtermDys acting as a dominant negative competitor of dystrophin and suggest 
that the presence of this protein may contribute significantly to the 
cardiomyopathy caused by EV infection. 
 Using immunofluorescence, we found that the CtermDys protein localized 
to the sarcolemma.  We also observed a ~5-10 fold increase in expression of 
other DGC proteins at the membranes of CtermDys mice.  This suggests that the 
sarcolemma has a reserve capacity to accommodate DGC protein complexes 
which is limited by the availability of dystrophin (or other β-dystroglycan binding 
proteins, such as CtermDys).  This assertion is also supported by previous 
findings which show that transgenic overexpression of sarcoglycans does not 
result in increased expression of other DGC proteins [46,47].  Additionally, 
expression the CtermDys protein caused a ~70% reduction in dystrophin.  To 
explain these data, we hypothesize that the CtermDys protein nucleates a novel 
CtermDys-DGC complex which exhausts the sarcolemma's ability to 
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accommodate DGC proteins, then competes with the native DGC for residency 
at the sarcolemma.  However, at the current time we cannot exclude the 
possibility of CtermDys competing directly with dystrophin for incorporation into 
already formed DGC.  Additionally, we propose that this cardiomyopathy is not 
caused directly by expression of the CtermDys transgene, but is instead due to 
replacement of the DGC with a CtermDys-DGC, which is hypofunctional due to 
its inability to tether actin and β-dystroglycan.  Interestingly, 5-10 fold increase of 
expression of DGC proteins in the hearts of CtermDys transgenic mice was 
insufficient to prevent dystrophic cardiomyopathy, strongly emphasizing the 
importance of dystrophin's role as mechanical tether.   
Expression of the CtermDys transgene also increased susceptibility of the 
heart to ischemic injury as shown by reduced recovery of systolic and diastolic 
function during reperfusion.  This finding has clinical significance in light of 
previous findings by Andreoletti and colleagues [1] that showed EV infection 
increases susceptibility of the heart to ischemic injury.  Collectively, these results 
show that expression of the C-terminal product of dystrophin cleavage by 2Apro is 
sufficient to cause dystrophic cardiomyopathy and increase susceptibility to 
ischemic injury.  Because the products of dystrophin cleavage by 2Apro have 
been observed following EV infection along with reductions in dystrophin, these 
findings suggest the presence of CtermDys and loss of dystrophin may contribute 
significantly to the pathogenesis of EV infection. 
 Because 2Apro cleavage of dystrophin results in production of both N- and 
C-terminal dystrophin fragments, we also determined the effects of NtermDys 
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expression on the heart.  Compared to dystrophin at the CtermDys protein, 
NtermDys localized diffusely throughout the myocardium, but was enriched at the 
sarcolemma and nucleus.  This is in agreement with previous findings showing 
similar sarcolemmal localization of modified dystrophin proteins lacking only the 
dystroglycan-binding domain [48].  The mechanism by which the NtermDys 
protein traffics to the sarcolemma is not clear but may involve binding to 
cytoskeletal actin or direct interactions with membrane phospholipids [49].  The 
NtermDys protein also localized strongly in the nucleus of cardiac myocytes 
through mechanisms which are not clear and warrant further study.  However, we 
speculate that the actin binding activity of NtermDys dictates its localization in 
cardiac myocytes.  This explains the presence of the NtermDys protein near the 
sarcolemma and its striated pattern of expression.  Additionally, actin is also 
present in the nucleus [50] which may explain the nuclear localization of 
NtermDys.  To my knowledge, no previous study has shown nuclear localization 
of dystrophin or any engineered dystrophin protein.  A previous report has shown 
that a disease-causing mutation in δ-sarcoglycan causes its retention in the 
nucleus, but it unclear at this time if the mechanism of nuclear localization is 
similar to that which occurs in NtermDys mice [46].  NtermDys mice show normal 
expression and localization of DGC proteins and no evidence of sarcolemmal 
instability (Figures 4-2,4-3, 4-6).   
 In order to simulate the effects of dystrophin cleavage by 2Apro in the 
myocardium most accurately, we created double transgenic mice expressing 
both NtermDys and CtermDys in the heart.  These mice show dystrophic 
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cardiomyopathy, as shown by enhanced sarcolemmal instability which was 
similar to CtermDys and mdx mice.  These findings, along with those in single 
transgenic mice show that expression of CtermDys causes dystrophic 
cardiomyopathy and that expression of NtermDys has no detrimental effects on 
the heart.  Additionally, because double transgenic mice essentially replace intact 
dystrophin with 2 proteins expressing all of its functional domains, but collectively 
lack the ability to tether actin to β-dystroglycan, this again suggests that 
dystrophin's primary function in the cardiac myocyte is to act as a mechanical 
tether.  This is in agreement with a previous report showing that expression of all 
dystrophin functional domains in trans does not correct dystrophy in mdx skeletal 
muscle [51]. 
 When relating the phenotype of these transgenic mice to the pathogenesis 
of EV infection, it is important to consider differences in the mechanism by which 
dystrophin expression is reduced.  During EV infection, 2Apro causes cleavage 
and loss of dystrophin concomitant with production of both the N- and C-terminal 
cleavage products.  Alternatively, expression of the CtermDys transgene causes 
a ~70% reduction in dystrophin content at the sarcolemma likely through 
competition for binding with β-dystroglycan.  We speculate that the CtermDys 
transgene is overexpressed relative to endogenous dystrophin at a molar level 
due to the significant increase in DGC proteins in the hearts of CtermDys mice.  
However, in each case, expression of dystrophin at the sarcolemma is reduced 
and replaced with expression of the products of dystrophin cleavage by 2Apro.  
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Thus, we propose that transgenic expression of NtermDys and CtermDys models 
the effects of 2Apro-mediated cleavage of ~70% of dystrophin on the heart. 
 In addition to studying the effects of dystrophin cleavage by 2Apro on a 
wild-type background, we also crossed the CtermDys transgene onto the 
dystrophin-deficient mdx background.  Previous reports have shown that 
expression of short, dystroglycan-binding isoforms of dystrophin exacerbate the 
dystrophic phenotype of mdx skeletal muscle [32,34].  The data set for this 
comparison is still rather nascent, but we observed a non-significant trend toward 
enhanced membrane instability in CtermDys(mdx) mice compared to mdx mice.  
However, expression of the CtermDys transgene did not enhance susceptibility 
to ischemic injury in mdx mice.  Further study and enhancement of group sizes 
are ongoing to determine if there is a statistically significant and physiologically 
relevant effect of the CtermDys protein on the hearts of mdx mice. 
 In this study, we have shown that expression of the β-dystroglycan-binding 
CtermDys protein is sufficient to cause dystrophic cardiomyopathy.  The 
significance of these findings lie in the identification of 2Apro-mediated dystrophin 
cleavage as a novel target for therapeutic intervention in EV infection, a clinically 
relevant disease process. 
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Figures 
 
Figure 4-1.  Creation of transgenic mice and transgene expression.  A) Top, 
Schematic of dystrophin structure.  Hinge domains are indicated by red boxes.  
Spectrin-like repeats are indicated by blue boxes, with light blue boxes 
constituting the rod domain actin binding region of dystrophin.  Dotted line within 
Hinge 3 indicates 2Apro cleavage site.  Lower, Schematic of the NtermDys and 
CtermDys transgenes with N-terminal epitope tags.  NtermDys contains an N-
terminal flag epitope tag, the N-terminal domain of dystrophin, and the N-terminal 
portion of the central rod domain (including spectrin-like repeats 1 through 19 
and hinges 1, 2, and part of hinge 3).  CtermDys contains an N-terminal myc 
epitope tag, dystrophin's cysteine-rich domain, C-terminal domain, and C-
terminal portion of the rod domain (containing part of hinge 3, hinge 4, and 
spectrin-like repeats 20-24).  B) Left, Western blot for NtermDys protein in 
representative samples of total protein from non-transgenic (NTg) littermates and 
NtermDys transgenic lines.  Predicted MW of NtermDys – 283 kDa.  NtermDys 
protein was detected with an anti-flag antibody and an anti-dystrophin antibody 
(mid rod) which also detected dystrophin.  Right, Quantification of transgene 
expression in NtermDys transgenic lines, shown as expression relative to loading 
normalized to line 368.  C) Left, Western blot for CtermDys protein in 
representative samples of total protein from NTg and CtermDys transgenic lines.  
CtermDys protein was detected with an anti-flag antibody and an anti-dystrophin 
antibody (C-terminal) which also detected dystrophin.  Intervening lanes of same 
blot removed for clarity.  Right, Quantification of transgene expression in 
CtermDys transgenic lines, shown as expression relative to loading normalized to 
line 1.  Data expressed as mean ± SEM.  N = 4-6 per group. 
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Figure 4-2.  DGC protein expression at the membrane in hearts of 
transgenic mice.  A) Left, representative Western blot for dystrophin expression 
in non-transgenic (NTg), CtermDys, and NtermDys mice.  Right, quantification of 
dystrophin expression shown as expression relative to loading normalized to 
NTg.  B) Representative western blot and quantification of β-dystroglycan 
expression in transgenic mice.  C) Representative western blot and quantification 
of γ-sarcoglycan expression in transgenic mice.  D) Representative western blot 
and quantification of α-sarcoglycan expression in transgenic mice.  E) 
Representative western blot and quantification of α-dystroglycan expression in 
transgenic mice.  .  Intervening lanes of same blot removed for clarity.  Data 
expressed as mean ± SEM.  N = 4-7 per group.  Quantification of protein 
expression shown as expression relative to loading normalized to NTg.  * - P < 
0.05 vs. NTg. 
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Figure 4-3.  Subcellular localization the NtermDys protein and β-
dystroglycan in the heart. Immunofluorescent detection of laminin (A, B) and 
the NtermDys protein (C, D) in non-transgenic (NTg) mdx  and NtermDys(mdx) 
hearts.  E, F - Merged images.  Scale bar – 100 µm. 
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Figure 4-4.  Nuclear localization of the NtermDys protein in the heart.  Nuclei 
shown with DAPI (A, B).  Immunofluorescent detection of the NtermDys protein 
(C, D) and laminin (E, F) in non-transgenic (NTg) mdx  and NtermDys(mdx) 
hearts.  G, H - Merged images. Subcellular localization of β-dystroglycan in mdx 
(G) and NtermDys(mdx) (H) hearts.    Scale bar - 50 µm. 
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Figure 4-5.  Subcellular localization the CtermDys protein and β-
dystroglycan in the heart. Immunofluorescent detection of laminin (A, B) and 
the CtermDys protein (C, D) in non-transgenic (NTg) and CtermDys hearts.  E, F 
- Merged images.  Subcellular localization of β-dystroglycan in NTg (G) and 
CtermDys (H) hearts.  Scale bar - 100 µm. 
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Figure 4-6.  Membrane stability in hearts of transgenic mice.  A) 
Quantification of % EBD positive area in transgenic mice and non-transgenic 
(NTg) littermates.  Data expressed as mean ± SEM.  N = 4-17 per group.  * - P < 
0.05 vs. NTg.  B) Representative mosaic images EBD uptake in hearts of NTg 
(B), NtermDys368(C), NtermDys367(D), NtermDys10(E), NtermDys13(F), 
CtermDys4(G), double transgenic (DTg, H),  non-transgenic mdx (mdx, I), 
NtermDys368(mdx) (J), Cterm4(mdx) (K). 
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Figure 4-7.  Fibrosis in hearts of transgenic mice.  Sirius Red-Fast Green 
staining of non-transgenic (NTg), NtermDys, CtermDys hearts, and mdx hearts.  
Mosaic images of NTg (A), NtermDys (C), CtermDys (E), and mdx (G) hearts.  
Higher magnification images of NTg (B), NtermDys (D), CtermDys (D), and mdx 
(F) hearts.  Scale bar = 200 µM. 
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Figure 4-8.  Susceptibility to ischemic injury in isolated hearts of transgenic 
mice.  Systolic (A) and diastolic (B) function of non-transgenic (NTg) and 
CtermDys hearts during ischemia/reperfusion.  Systolic (C) and diastolic (D) 
function of NTg(mdx) and CtermDys(mdx) hearts during ischemia/reperfusion.  
E) Recovery of systolic function in hearts of transgenic mice and non-transgenic 
littermates.  Data expressed as mean ± SEM.  N = 3-12 per group.  * - P < 0.05 
vs. NTg. 
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Chapter 5 
 
Discussion 
 
 
In this dissertation I have made significant new findings regarding the role of 
dystrophin in the heart.  Specifically, I have carried out studies characterizing 
novel mechanisms by which loss of functional dystrophin in the heart causes 
disease in DMD and non-inherited heart diseases.  Summarized below are the 
major findings of these studies and their relevance to the field. 
 
Summary of significant results 
 Inbred mouse strains show significant divergence in cardiac function.  
Inbred mouse strains are extremely common in modern biomedical research.  
The genetic homogeneity of these mice allows for exquisite control and 
reproducibility experiments.  However, because many different strains of inbred 
mouse are commonly used (over 450 inbred mouse strains have been 
described), comparing studies in which different inbred strains have been utilized 
can be challenging.  Numerous previous reports have shown that inbred strains 
show significant divergence in various measures of physiological function.  In 
chapter 2, I have described strain-specific differences in cardiac function of 
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several commonly used inbred mouse strains using  2 commonly utilized 
techniques: the ex vivo perfused heart preparation and in vivo hemodynamic 
analysis using conductance micromanometry.  I assessed cardiac performance 
using these techniques at baseline and during physiologically relevant stress and 
found significant divergence between enormous inbred strains.  These 
differences were not consistent between the ex vivo and in vivo techniques, 
suggesting that researchers should consider both the strain of inbred mice and 
the technique used to assess function when designing experiments.  Additionally, 
the findings of this study shed light on the mild dystrophic phenotype of mdx mice 
when compared to DMD patients.  Mdx mice are bred onto the C57BL/10SnJ 
genetic background, which showed no marked resistance to cardiac stress and 
injury compared to other common inbred strains.  This suggests that the mild 
phenotype of mdx mice is not due genetic background effects and is more likely 
caused by fundamental physiologically difference between mice and humans.  
Upregulation of utrophin, which has not been convincingly shown to occur in 
humans, is commonly believed to contribute to the mild phenotype of mdx mice 
[1,2,3].  More recently, loss of function mutations of CMAH in humans have also 
been identified which worsen dystrophy when knocked into the counterpart 
mouse locus [4]. 
 
 The DGC is a critical determinant of whole-organ cardiac compliance.  
Previously, our lab and others have demonstrated that mechanical instability of 
the sarcolemma is a primary cellular defect in DMD [5].  Additionally, our lab has 
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previously shown that instability of the membrane causes reduced mechanical 
compliance in isolated cardiac myocytes through aberrant influx of calcium 
across the sarcolemma [5].  To expand upon and translate these findings from 
single cells to whole organs, I subjected isolated dystrophin-deficient (mdx) 
hearts to whole-organ stretch ex vivo.  Unexpectedly, I found that mdx hearts 
show increased whole-organ compliance compared to normal hearts as shown 
by blunted increases in LVEDP as LV volume increases above 8 mmHg.  In 
previous studies, influx of extracellular calcium through sarcolemmal “micro-
tears” was identified as a key moderator of increased single cell compliance in 
isolated mdx myocytes, which could be rescued using the membrane sealant 
poloxamer 188 (P188) [5].  To determine the role of membrane damage and 
extracellular calcium influx on the increased compliance observed in isolated 
mdx hearts, whole-organ compliance was determined at varying perfusate 
calcium concentrations and in the presence of P188.  From these studies I found 
that the increased whole-organ compliance of mdx hearts was independent of 
perfusate calcium concentration and was not affected by perfusion with P188.  I 
also found that increased whole-organ compliance in isolated hearts was not 
associated with greater excursions in sarcomere length of mdx hearts.  This 
suggests that the determinants of whole-organ compliance are not a simple 
extrapolation of findings in single cells.   
Based upon these findings, I proposed a novel model for ventricular 
dilation in the dystrophin-deficient heart through side-to-side translation, or 
slippage, of myocytes past each other during mechanical distention.  In this 
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model, slippage is caused by disruption of the DGC-mediated linkage between 
cardiac myocytes and the extracellular matrix.  Additional studies in other genetic 
models of dystrophy showed similar findings in models where the DGC or its 
extracellular binding partner laminin were disrupted, suggesting that alterations in 
cell-extracellular matrix contacts may be a common mechanism for pathological 
left ventricular dilation in multiple forms of muscular dystrophy.  Mice lacking the 
membrane repair protein dysferlin showed normal compliance.  These findings 
are consistent with the proposed model of enhanced myocardial compliance 
caused by myocyte slippage and suggest that the mechanical linkage provided 
by the DGC is a crucial determinant of the whole-organ mechanical properties of 
the heart.   
These findings provide insight into a novel mechanism of heart disease in 
muscular dystrophy.  Many forms of muscular dystrophy are associated with 
cardiomyopathy with some showing increased propensity to develop DCM.  
Since many muscular dystrophies are hypothesized to be caused by fundamental 
defects in mechanical membrane stability, it unclear why certain dystrophies 
cause DCM at a higher rate than others.  Here, I suggest a novel mechanism for 
the pathological dilation of the ventricular during dystrophy through disruption of 
the DGC.  Clinical data support this hypothesis, as mutations in dystrophin, 
laminin-α2, and β-sarcoglycan frequently cause dilated cardiomyopathy whereas 
mutations in dysferlin do not [6,7,8,9,10,11].  This provides strong evidence that 
the measurements made in Chapter 3 provide direct insight into the mechanisms 
of pathological LV dilation.  With regard to alternative mechanisms for the 
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reduced compliance observed in dystrophic hearts, dystrophy often causes 
fibrosis within the myocardium which may alter passive compliance.  However, 
previous reports have shown that enhanced cardiac collagen content, as 
observed in the tight-skin mouse, does not alter the passive compliance of the 
myocardium [12].  Additionally, studies in our lab have shown that individual, 
membrane-permeabilized cardiac myocytes from mdx mice show no differences 
in passive compliance, suggesting that altered compliance is not caused by the 
sarcomeric protein titin [13].  
 
 C-terminal product of 2Apro-mediated dystrophin cleavage is sufficient to 
cause dystrophic cardiomyopathy.  As described in Chapters 1 and 4 of this 
thesis, cardiac enterovirus infection is a clinically relevant disease process which 
is involved in both acute and chronic cardiac dysfunction [14,15,16,17,18,19].  
The precise mechanisms by which enterovirus infection causes cardiomyopathy 
are still being investigated.  Previously, it has been shown that 2Apro, a protease 
expressed by enteroviruses, cleaves dystrophin within the hinge 3 domain 
[20,21].  The putative C-terminal product of 2Apro-mediated cleavage of 
dystrophin is structurally similar to some naturally occurring non-muscle isoforms 
of dystrophin, including Dp71 and Dp116 [22,23].  These proteins contain 
dystrophin’s dystroglycan-binding domains, but lack its actin-binding domains.  
Previously, it has been shown that expression of these short isoforms of 
dystrophin cause dystrophic myopathy when transgenically expressed in normal 
skeletal muscle [24,25,26,27].  These studies suggested that the short isoforms 
173 
of dystrophin act as a dominant negative to full-length dystrophin, competing for 
incorporation into the DGC at the sarcolemma and essentially replacing 
dystrophin with a less functional protein.  Based on these findings, I hypothesized 
that the C-terminal product of dystrophin cleavage by 2Apro would act in a similar 
dominant negative fashion in the heart and cause dystrophic cardiomyopathy.  
To test this hypothesis, I created transgenic mice which transgenically express 
the putative C-terminal fragment of dystrophin cleavage by 2Apro.  
 The C-terminal dystrophin transgene (CtermDys) localized to the 
sarcolemma, as shown by immunofluorescence, and the CtermDys protein can 
also be purified with integral and peripheral membrane proteins, including the 
DGC.  Expression of the CtermDys transgene causes a 70% reduction in 
expression of full-length dystrophin at the membrane.  Additionally, expression of 
CtermDys causes a ~5-10 fold increase in expression of other DGC proteins.  
The elevation in DGC proteins above normal levels in CtermDys transgenic mice 
suggests that the content of dystrophin is the rate-limiting step in incorporation of 
DGC complexes into the sarcolemma.  Collectively, these findings support the 
hypothesis that CtermDys exerts a dominant negative effect on DGC function.  It 
is not currently clear whether CtermDys competes directly with dystrophin for 
binding to β-dystroglycan at the already formed DGC or if the CtermDys-DGC 
competes with native DGC for residency at the sarcolemma. 
 Since enterovirus infection has been associated with dilated 
cardiomyopathy and increased susceptibility to death following acute myocardial 
infarction at a very high rate (20-40%), I tested the response of CtermDys 
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transgenic mice to ischemic injury using an ex vivo ischemia and reperfusion 
injury.  Expression of the CtermDys transgene is sufficient to cause increased 
susceptibility to ischemic injury.  Since the putative products of dystrophin 
cleavage by 2Apro have been observed following cardiac enterovirus infection 
[20], this is a clinically relevant finding suggesting that loss of functional 
dystrophin through 2Apro cleavage contributes to heightened risk of cardiac 
dysfunction following ischemic injury. 
 The N-terminal product of 2Apro-mediated dystrophin cleavage (NtermDys) 
does not contain the DGC binding domain of dystrophin and thus was not 
predicted to interact with the DGC or cause dystrophic cardiomyopathy.  
However, previous reports have shown that modified dystrophin proteins which 
lack its dystroglycan-binding domains still localize to the sarcolemma, but do not 
correct muscular dystrophy when expressed in dystrophin deficient muscle 
[28,29,30].  The localization of these proteins at the sarcolemma in the absence 
of dystroglycan binding is hypothesized to be due to direct interactions between 
dystrophin and membrane phospholipids [31].  In agreement with these previous 
results, I found that the NtermDys protein localized to the sarcolemma and was 
found in the membrane fraction.  However, unlike CtermDys, expression of 
NtermDys did not affect expression of dystrophin or other DGC proteins.  
Curiously, the NtermDys protein also trafficked to the nucleus through 
mechanisms which are not clear but may involve its actin binding activity.    
 NtermDys transgenic mice did not show dystrophic cardiomyopathy as 
shown by normal EBD uptake.  This is in agreement with our hypothesis that 
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expression of a truncated dystrophin protein does not, per se, cause 
cardiomyopathy.  However, as in the case of the CtermDys transgenic mice, 
truncated dystrophin proteins that can bind β-dystroglycan have the potential to 
cause dystrophic cardiomyopathy if they also lack actin binding function. 
 Since cleavage of dystrophin by 2Apro during enterovirus infection causes 
the creation of both N- and C-terminal cleavage products, I crossed CtermDys 
and NtermDys mice together to generate double transgenic mice.  These mice 
showed dystrophic cardiomyopathy as shown by increased EBD uptake which 
was similar to both mdx and CtermDys mice.  This supports my hypothesis that 
expression of the CtermDys protein causes dystrophic cardiomyopathy which is 
not contributed to by the NtermDys protein.  
 In addition to studying the effects of the CtermDys and NtermDys proteins 
on the normal myocardium, I also crossed these transgenic mice onto the 
dystrophin-deficient mdx mouse line.  Although these studies do not have direct 
relevance to the cardiomyopathy of cardiac enterovirus infection, no previous 
studies have expressed truncated dystrophin fragments structurally similar to the 
NtermDys and CtermDys transgenes in the heart.  Therefore, crossing these 
lines onto the mdx background provides insight into the structural basis for 
dystrophin function in the heart.  This information could then be used in the 
design of truncated, functional dystrophin isoforms for delivery and treatment of 
DMD  
 CtermDys mice crossed onto an mdx background (CtermDys(mdx)) 
showed membrane instability as shown by increased EBD uptake.  The level of 
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EBD uptake was higher than non-transgenic, but similar to mdx mice.  
Additionally, CtermDys(mdx) hearts showed impaired recovery of function 
following ex vivo ischemic injury compared to wild-type mice, but were similar to 
mdx hearts.  These results suggest that the CtermDys protein does not act as a 
dominant negative to utrophin by competing for occupancy the DGC.  
Additionally, since CtermDys(mdx) mice show a similar phenotype to mdx mice 
despite increased expression of DGC proteins at the sarcolemma, this provides 
further evidence that the non-mechanical function of dystrophin plays a relatively 
minor role in the prevention of dystrophy and maintenance of heart function. 
 NtermDys(mdx) mice showed dystrophic cardiomyopathy as shown by 
increased EBD which was significantly greater than wild-type mice but equivalent 
to mdx mice.  This finding is in agreement with our hypothesis that the NtermDys 
protein does not affect membrane stability.   
 
Future directions 
 Investigating the mechanisms of pathological LV dilation in muscular 
dystrophy.  As discussed above, I have proposed a novel mechanism for the 
pathological dilation of the LV in some forms of muscular dystrophy.  Specifically, 
in this thesis I have shown increased compliance of the dystrophin-deficient 
myocardium which when correlated with our measurements of sarcomere length 
suggest that changes in sarcomere length do not track with changes in LV 
volume.  Using these data I hypothesized that disruption of the DGC causes 
myocytes to translate or "slip" past each other, providing a mechanism by which 
177 
greater excursions in LV volume occur without greater changes in LV volume of 
mdx hearts.  However, sarcomere length was not measured directly during 
stretch due to technical limitations.  Instead, hearts were pressure-clamped at 
given LV pressures, fixed and sectioned for the measurement of sarcomere 
length by immunofluorescence.  Although the data generated support this model 
of LV dilation, it has not been shown directly that mechanical stretch causes 
slippage of cardiac myocytes past each other to a greater degree in the 
dystrophin-deficient myocardium.  Currently, the technical capability exists to 
carry out experiments to answer this question.  Specifically, applying mechanical 
stretch to isolated trabeculae while visualizing sarcomeres utilizing confocal 
microscopy would allow for direct visualization of adjacent myocytes during 
stretch.  From these recordings, the contribution of myocyte slippage during 
mechanical stretch of the myocardium could be determined.  Carrying out this 
experiment on wild-type and mdx trabeculae would provide invaluable data to 
directly determine if myocyte slippage is enhanced in the absence of dystrophin.   
 Although previous reports have shown that mdx mice show no evidence of 
enhanced fibrosis in the myocardium at the ages tested in Chapter 3 [32], we 
cannot exclude that alteration in the micro- or macrostructure of collagen within 
the extracellular matrix did not contribute to the enhanced compliance of isolated 
dystrophic hearts.  To directly probe the mechanical properties of the 
exctracellular matrix, I propose to decellularize the heart using SDS as previously 
described by Ott and colleagues [33].  The decellularized matrix lacks all cells but 
retains extracellular collagen [33].  Performing a stress-strain analysis will then 
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determine if alterations in collagen may contribute to altered compliance of 
dystrophic hearts. 
 Determination of whole-organ compliance in other genetic models of 
DCM.  As discussed above, chapter 3 of this thesis characterizes whole-organ 
cardiac compliance in various genetic models of muscular dystrophy.  From 
these data, I hypothesized that cell-cell slippage of cardiac myocytes contributes 
to the pathological dilation of the LV that occurs in many forms of muscular 
dystrophy.  The common mechanistic link between increased whole-organ 
compliance and LV dilation is disruption of the DGC or other proteins which 
facilitate cell-extracellular matrix linkages.  However, not all forms of DCM are 
caused by mutations which directly affect cell-extracellular matrix interactions.  
For instance, it has previously been shown that DCM can be caused by 
mutations in sarcomeric proteins, specifically cardiac troponin I, cardiac troponin 
C, cardiac troponin T, and α-tropomyosin [34,35,36,37,38].  Since sarcomeric 
proteins are not directly involved in cell-extracellular matrix contacts, I do not 
expect them to show enhanced slippage.  If this is the case, these studies would 
still be of value in identifying divergent mechanisms for the development of DCM.  
However, a finding of similar changes in whole-organ compliance between 
dystrophic and sarcomeric mutant hearts could reveal myocyte slippage to be a 
potential common pathway for the development of DCM in numerous disease 
states.  To determine if myocyte slippage contributes to LV dilation in these mice, 
I propose that similar studies to those described in Chapter 3 be carried out on 
transgenic mice that express these sarcomeric DCM proteins to determine 
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whole-organ cardiac compliance and to track sarcomere length during whole-
organ stretch.  At least one transgenic mouse expressing a sarcomeric DCM 
mutant protein exists [39].   
  
 Investigating the mechanisms of cardiomyopathy caused by enterovirus 
infection.  As discussed in the first chapter, a significant body of research 
suggests that enterovirus infection causes cardiomyopathy through cleavage of 
dystrophin by 2Apro.  Specifically, previous studies have shown that enterovirus 
infection causes fragmentation of dystrophin in vitro and in vivo [20,21].  
Dystrophin was identified as a substrate for 2Apro, providing a mechanistic 
explanation for its cleavage [20] with further studies identifying the putative site 
within the hinge 3 domain [21].  Additionally, expression of the entire 
coxsackievirus genome or the 2Apro gene alone causes cardiomyopathy [40,41].  
However, it should be mentioned that although it is clear that expression 2Apro 
causes cardiomyopathy, it is not totally clear whether this is due to cleavage of 
dystrophin.  In the study referenced above by Xiong et al, transgenic expression 
of 2Apro causes cardiomyopathy, but no evidence of dystrophin cleavage (by 
Western blot) was shown [40].  Additionally, the authors assert that expression of 
2Apro causes dystrophic cardiomyopathy as shown by increased Evans blue dye 
uptake [40].  However, the data published shows only a handful of cardiac 
myocytes by immunofluorescence and it should be noted when interpreting this 
data that 2Apro cleaves numerous substrates which are essential to cell function 
[42,43,44].  Collectively, these results highlight a gap in knowledge regarding the 
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cleavage of dystrophin by 2Apro and its effects on cardiac function during 
enterovirus.  Specifically, although dystrophin fragmentation occurs following 
enterovirus infection and 2Apro cleaves dystrophin in vitro, evidence of dystrophin 
cleavage has not been observed following expression of 2Apro in vivo.  Although 
the reason for this obvious omission is not clear, I speculate that prolonged 
inhibition of protein translation through 2Apro-mediated cleavage of eIF4-G 
precludes detection of dystrophin and its cleavage products.  In previous in vivo 
studies of 2Apro activity, the protease is expressed for days or weeks prior to 
tissue harvest which may have led to loss of dystrophin through inhibition of 
protein translation rather than proteolytic cleavage [40,41].  To “catch” the 
cleavage of dystrophin by 2Apro before wholesale inhibition of protein translation 
precludes its detection, I propose studies involving acute treatment of isolated 
hearts with recombinant 2Apro conjugated to the TAT cell penetrating peptide to 
avoid long-term suppression of translation.  Previously, it has been shown that 
proteins conjugated to TAT are effectively able to cross the cell membrane and 
incorporate into the cytoplasm [45].  This study would allow for enhanced 
temporal control of dystrophin cleavage by 2Apro and could potentially document, 
for the first time, the presence of the putative products of 2Apro-mediated 
cleavage of dystrophin in intact cardiac myocytes.   
 The pathogenesis of enterovirus infection is a complex process caused by 
the detrimental functions of the viral proteins expressed during viral replication 
[46].  An aim of this thesis is to determine the contribution of dystrophin cleavage 
by 2Apro to the pathogenesis of enterovirus infection.  In Chapter 4, I have shown 
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that expression of the CtermDys protein is sufficient to cause cardiomyopathy 
when transgenically expressed.  However, because 2Apro cleaves numerous host 
substrates, the specific effect of dystrophin cleavage (distinguished from the 
effects of 2Apro cleaving other substrates) in the pathogenesis of cardiac 
enterovirus expression is not clear.  To determine the specific effects of 
dystrophin cleavage on the pathogenesis of enterovirus infection, I propose 
studies involving transgenic expression of a 2Apro-resistant micro-dystrophin 
during enterovirus infection.  Specifically, I propose to create transgenic mice 
expressing either normal hinge 3 microdystrophin or a modified hinge 3 
microdystrophin containing a point mutation within the hinge 3 domain which has 
previously been shown to confer resistance to 2Apro cleavage [21].  These mice 
would be crossed on an mdx background then infected with enterovirus as 
previously described [20] or could be delivered 2Apro by AAV-mediated gene 
transfer [47].  If the transgenic mice expressing 2Apro-resistant microdystrophin 
show improved cardiac function following enterovirus infection or 2Apro 
expression, this will show for the first time the specific role of dystrophin cleavage 
by 2Apro in the pathogenesis of enterovirus infection in the heart.   
 
 Determining the requirement for dystrophin in the heart.  Currently, there 
is a significant gap in knowledge regarding the level of dystrophin required to 
prevent dystrophy in skeletal and cardiac muscle.  Previous reports suggests that 
~30% of normal dystrophin can protect skeletal muscle from dystrophy [48,49].  
However, a more thorough study aimed at titrating in dystrophin to striated 
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muscle would help to clearly define the quantitative need for dystrophin and 
inform therapeutic goals for treatment of DMD.  This could be accomplished 
through several different approaches.  Previously, a group led by Dr. George 
Dickson created a short hairpin RNA (shRNA) construct which, when packaged 
into an adeno-associated virus (AAV) vector, is capable of knocking down 
dystrophin expression in skeletal muscle [50].  By delivering this vector to the 
heart using recombinant AAV as previously described [47,50], it would be 
possible to monitor dystrophin expression and the development of sarcolemmal 
instability (believed to be the fundamental defect in DMD) as dystrophin 
expression wanes.  I have acquired this reagent from Dr. Dickson and attempted 
in vivo gene knockdown of dystrophin.  However, my attempts were not 
successful due to technical problems in generating effective AAV vectors.  
Experiments are ongoing to make a second attempt at in vivo knockdown of 
dystrophin.   Alternatively, titrating dystrophin expression in the heart could be 
achieved through the use of transgenic mice expressing dystrophin by inducible 
promoters.  Using this approach, transgenic expression of dystrophin could be 
controlled using an inducible promoter such as the tetracycline-inducible 
promoter or the thyroid-responsive and cardiac-specific alpha myosin heavy 
chain promoter.  Treatment with 6-propyl 2-thiouracil has been shown to 
suppress expression from the alpha myosin heavy chain promoter and could be 
used to suppress transgene expression [51].   
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 Assessing the non-mechanical function of dystrophin in the heart.  As 
cited above, it has previously been shown that the non-muscle dystrophin 
isoform Dp116 exacerbates the dystrophic phenotype in skeletal muscle of mdx 
mice by exerting a dominant negative effect on the utrophin-glycoprotein complex 
present in mdx skeletal muscle [24].  However, a more recent study has shown 
that Dp116 can increase lifespan and improve histological signs of muscle 
wasting in skeletal muscle of dystrophin/utrophin double knockout (DKO) mouse 
[52].  This suggests that despite the inability of Dp116 to mechanically tether 
actin and β-dystroglycan, the signaling/scaffolding functions of dystrophin play a 
modest, yet significant role in maintaining the viability and function of skeletal 
muscle.  The mechanism of dystrophin's non-mechanical function may be related 
to its role in localizing numerous functionally significant proteins to the 
sarcolemma, including nNOS, diacylglycerol kinase-ζ, sodium channels, and 
TRPC channels [53,54,55,56,57,58].  The individual contributions each of these 
proteins hasn't been defined in most cases.  However, nNOS has been shown to 
play an important role in regulating vasoconstriction and blood flow to striated 
muscle during exercise [59].  The CtermDys transgene is structurally very similar 
to Dp116 and although its expression does not improve the phenotype of 
CtermDys(mdx) mice, it is possible that compensatory utrophin expression may 
be concealing some potentially beneficial effects of CtermDys expression.  
Therefore, I propose to cross the CtermDys transgene onto a dystrophin/utrophin 
double knockout background to determine if the non-mechanical functions of 
dystrophin improve cardiac function in a physiologically meaningful way.   
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 Effects of altering gap junction conductance on DMD cardiomyopathy.  As 
shown by myself in Chapter 4 and others [60], membrane instability in mdx 
hearts, as shown by EBD intake, occurs in focal lesions.  The reasons for this 
pattern of membrane instability are not clear, but have been hypothesized to 
occur through disruption of the myocardium entirely through regional mechanical 
stress.  Alternatively, it has been hypothesized that these focal lesions arise due 
to pathological extracellular calcium influx which is propagated to neighboring 
myocytes via gap junctions.  Previously, our lab has shown that membrane 
instability of isolated dystrophin-deficient cardiac myocytes predisposes them to 
catastrophic influx of extracellular calcium [5].  Normally, ionic conductance at 
gap junctions aids in propagating action potentials and synchronizing contraction 
of the myocardium.  However, in the dystrophin-deficient heart pathological 
calcium influx due to membrane instability may be propagated via gap junctions 
to neighboring cells and cause membrane instability in many more myocytes 
through mechanical stress brought on by calcium-induced hypercontracture.  In 
this model the initiating event is mechanical disruption of the membrane, but the 
propagation of myocardial damage occurs via conductance of calcium through 
gap junctions.  Therefore, limiting conductance through gap junctions may 
improve membrane stability in the dystrophic heart.  The central ion channel 
present in the gap junctions of cardiac myocytes is connexin43.  Connexin43-null 
mice are neonatal-lethal, but mice heterozygous for the knockout allele are 
viable, grossly indistinguishable from wild-type mice, and express ~50% of 
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normal connexin43 in the ventricles (expression of connexin40 and connexin45 
are unchanged in these mice) [61,62].  Although there is some controversy 
regarding the phenotype of connexin43 heterozygous mice, numerous reports 
have shown reduced conduction velocity in these mice [61,62,63,64].  Therefore, 
I propose crossing connexin43 heterozygous mice onto the dystrophin-deficient 
mdx background with the hypothesis that reduced conduction of calcium in gap 
junctions of connexin43 heterozygous(mdx) mice will reduce the size, but not the 
number, of EBD-positive lesions by inhibiting the spread of calcium from 
damaged cells to their neighbors.   The therapeutic value of these studies is 
questionable, since altering connexin43 content in the myocardium may be 
arrythmogenic.  However, from a basic science perspective, this study has the 
potential to enhance understanding the physiological processes by which loss of 
dystrophin causes focal membrane instability in the heart and ultimately leads to 
cardiomyopathy. 
 
 DMD-floxed exon mice to explore tissue-specific effects of dystrophin 
function.  Genetically modified mice have changed the way modern research is 
carried out.  These model organisms have permeated every field of biomedical 
research and allow for the study of individual genes in complex biological 
systems.  The development of inducible and tissue specific-promoter elements 
have allowed for further control of gene expression in genetically modified mice.  
This has been exploited thoroughly through the creation tissue-specific and 
inducible Cre recombinase expressing mice.  The Jackson Lab alone maintains 
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300 distinct Cre-expressing lines (http://jaxmice.jax.org/).  Investigators have 
exploited this technology thoroughly by using these Cre mice to modify gene 
expression in a spatio-temporal manner [65].  Despite the prevalence of this 
technology, it has not been applied with any vigor to the study of dystrophin and 
other products of the DMD gene.  Previously, a knockin mouse was created in 
which the entire DMD gene was floxed [66].  Our lab acquired these mice and I 
crossed them with multiple Cre-expressing lines [67,68] in an attempt to achieve 
efficient excision of the DMD gene in vivo.    I found that in vivo excision of the 
DMD gene was extremely inefficient, presumably due to the large size of the 
DMD gene.  The lack of an effective conditional-null model for products of the 
DMD gene is a gaping gap in the field.  I propose the creation of a knockin 
mouse harboring loxP sites around a rationally chosen exon of the DMD gene.  
This mouse would allow for spatio-temporal knockout of DMD gene expression 
dictated by Cre recombinase activity.  Choosing the appropriate exon is 
obviously crucial to the success of this mouse model, since not all exon deletions 
result in frameshift mutations and because compensatory splicing has been 
observed to avert or lessen disease caused by mutations in the DMD gene [69].  
Exon 66 is a suitable candidate exon to excise using this model.  Exon 66 is 86 
base pairs which, based on previous studies [67], should allow for high efficiency 
Cre-mediated recombination in vivo.  Deletion of exon 66 is predicted to cause a 
frameshift mutation leading to premature truncation of DMD proteins in the 
functionally crucial cysteine-rich domain.  Deletion of exon 66 causes DMD in 
human patients [70,71], although it is not clear if disease is caused by total loss 
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of dystrophin or by rendering dystrophin non-functional.  However, a similar 
mutation occurs in mdx3cv mice, a DMD mouse model created by ENU 
mutagenesis [72,73,74].  Importantly, deletion of this exon is predicted to disrupt 
all isoforms of the DMD gene (Figure 1-1).  However, the mdx3cv mouse does 
express ~5% of normal dystrophin despite the nonsense mutation it harbors in 
the DMD gene, suggesting some ability for compensatory splicing of dystrophin 
which may also be interesting to study [73].  Interestingly, a previous report 
described DMD with severe mental retardation in patients from 2 discrete families 
with mutations resulting in skipping of exon 66 from the dystrophin transcript [71].  
This suggests that mice with a floxed exon 66 may be used to study the neural 
aspects of DMD.  Therefore, when used in combination with tissue-specific Cre-
expressing mice this mouse could be used to study the functional effects of 
dystrophin expression in a range of different tissues.  This has clinical relevance 
since DMD is often associated with mental retardation which has been linked to 
loss of the "short" dystrophin isoforms Dp71 and Dp140 [75].  Previous studies 
comparing mdx (which express Dp260, Dp140, and Dp71) and mdx3cv mice 
found phenotypic differences in behavior between these two DMD mouse 
models, supporting the role of the short isoforms of dystrophin in physiological 
function of the brain [76].  However, these mice lack the temporal and tissue-
specific control of dystrophin isoform expression required for more mechanistic 
studies of cognitive defects.   
 Collectively, a DMD-floxed-exon mouse along with modern Cre-
expressing lines could be used to study the products of the DMD gene in ways 
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that are currently not possible.  This mouse would be of great interest to 
researchers studying DMD, but also to others interested in dystrophin function in 
a broader sense. 
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